

1244709

'TWO AND TWO WHOLE INCHES PRESENTLY SHOWN COMBINED'

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

*November 02, 2004*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/567,771  
FILING DATE: *May 05, 2004*  
RELATED PCT APPLICATION NUMBER: PCT/US04/33391

Certified by

Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office



BEST AVAILABLE COPY



Atty. Dkt. No. 036481-0151

22264 U.S.PTO  
60/56771



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ralph Patrick BRAUN et al.

Title: Method

Appl. No.: Unknown

Filing Date: May 5, 2004

Examiner: Unknown

Art Unit: Unknown

**PROVISIONAL PATENT APPLICATION**  
**TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(c) is the provisional patent application of:

Ralph Patrick BRAUN  
8551 Research Way Blvd.  
Middleton, WI 53711

Lichun DONG  
8551 Research Way Blvd.  
Middleton, WI 53562

Applicant claims small entity status under 37 CFR 1.27(c)(1).

Enclosed are:

- Specification (80 pages).
- Formal drawings (44 sheets, Figures 1-28).
- Application Data Sheet (37 CFR 1.76).



Atty. Dkt. No. 036481-0151

The filing fee is calculated below:

	Rate	Fee Totals
Basic Fee	\$160.00	\$160.00
[ ] Small Entity Fees Apply (subtract 1/2 of above):	=	\$0.00
TOTAL FILING FEE:	=	\$160.00

A check in the amount of \$160.00 to cover the filing fee is enclosed.

The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.



Further, Applicant, by and through his attorney of record, hereby expressly abandons the application as of the filing date of this letter. This is an abandonment of the application only, and is not to be construed as an abandonment of the invention disclosed in the application. It is respectfully requested that the Office acknowledge abandonment of the application as of the filing date of this letter in a communication mailed to the undersigned.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 5 May 2004

By   
for   
Richard C. Peet  
Attorney for Applicant  
Registration No. 35,792

FOLEY & LARDNER LLP  
Customer Number: 27476  
Telephone: (202) 672-5483  
Facsimile: (202) 672-5399

## METHOD

The present invention provides a method or process for enhancing a CMI response to a  
5 nucleotide sequence of interest (NOI) encoding at least one epitope of interest (EOI) of a target antigen (TA).

More particularly, the method or process of the present invention for enhancing a CMI response may be used to prevent and/or treat a T cell mediated immune disorder.

10 The present invention also provides an activated T lymphocyte cellular (T-cell) obtainable by the described method or process.

15 The invention also relates an assay method for identifying candidate agents capable of enhancing or modulating a CMI response and to methods of preventing and/or treating a CMI disorder using the identified candidate agents.

## BACKGROUND TO THE INVENTION

Traditional vaccines and adjuvants stimulate humoral and to varying degrees, cellular  
20 responses through the administration of a “priming” agent comprising an antigen followed by a secondary or a “boosting” agent comprising additional antigen which is administered to the immune system after it has been efficiently primed with the priming agent.

25 The success of traditional prophylactic vaccines is largely dependent on the induction of a humoral (ie antibody) response. Typically a minimum time interval of about four weeks (ie about 28 days) between prime and boost vaccination is required for antibody production. In contrast the success of therapeutic vaccines is less dependent on an antibody response and more dependent on a cellular mediated immune (CMI) response.

Pertmer *et al* (1995) 13: 1427-1430) have demonstrated that a relatively long time interval (ie in terms of weeks) between prime and boost vaccinations will result in an enhanced CMI response in terms of CTL production. In addition, Prayaga *et al* ((1997) 12/13: 1349-1352) have shown that, in general, when a longer time interval between immunisations is 5 used, a better CTL response is obtained. Whilst there is no evidence that a time interval between prime and boost immunisations of less than 28 days would not be effective in terms of inducing an enhanced CMI response, the received wisdom in the field has been that a relatively long time interval (typically in terms of weeks) is required to elicit an effective CMI response.

10

As very little information is available about vaccination strategies capable of inducing an accelerated enhanced CMI response, there remains a need for optimisation of an NOI administration schedules that specifically induce an enhanced CMI response. A strategy for the rapid induction of a CMI response would be very beneficial for the treatment of a 15 wide range of immune, inflammatory and infectious diseases and disorders.

There also remains a need for both the development of techniques for the rapid identification of candidate agents such as epitopes and/or adjuvants and/or biological response modifiers capable of enhancing a CMI response and candidate agents capable of 20 modulating an enhanced CMI response. Previous assay methods for the identification of CMI-inducing epitopes have suffered a number of drawbacks. The most notable of which are the requirement for multiple injections of the candidate agent to be tested in combination with a wait of up to 4 weeks (ie at least about 28 days) or longer to determine whether the candidate agent had a positive effect on the CMI response and the general need 25 to include a modifier, such as an adjuvant with the candidate agent being tested for its capability to enhance a CMI response. Clearly, a method for the rapid identification of agents with a CMI inducing capacity is also of vital importance in the design of preventative and therapeutic strategies in relation to a wide variety of diseases.

### 30 SUMMARY OF THE INVENTION

The present invention provides a method or process for enhancing the CMI response *in vivo*. This approach provides a practical tool for enhancing the CMI response to an NOI

encoding at least one EOI of a TA by inducing early enhanced CMI activity over a relatively short period of time. The invention is based on the surprising finding that at least two administrations of an NOI encoding at least one EOI of a TA at intervals of from about 48 hours to about 144 hours between administrations significantly amplifies the CMI 5 response to at least one EOI of a TA. The finding that the NOI administration regime is so effective at eliciting an early enhanced CMI response is completely unexpected and contrary to the perceived wisdom in the field that a relatively longer time interval (typically in terms of weeks) rather than a shorter time interval (typically in terms of days) would be required to elicit an enhanced CMI response.

10

The enhanced CMI response may be used prophylactically and therapeutically to immunomodulate the CMI response to one or more EOI of a TA. The time course of the induced CMI response enables an effective strategy to be developed for immunotherapy of pre-existing T cell mediated disorders as well as facilitating broad protection against 15 subsequently encountered antigens. The present invention also provides a rapid method for the identification of candidate agents capable of enhancing or modulating a CMI response. This assay method is broadly applicable to both screening and vaccination, and is relevant to the development of prophylactic and/or therapeutic vaccines using the identified candidate agents.

20

#### ASPECTS OF THE INVENTION

In one aspect, the present invention provides a method of eliciting an enhanced cellular mediated immune (CMI) response against at least one target antigen (TA) in a host mammalian subject; wherein the method comprises administering a nucleotide sequence of 25 interest (NOI) encoding one or more epitopes of interest (EOI) of the TA at least twice to the host mammalian subject; wherein the intervals between each NOI administrations ranges from about 48 hours to about 144 hours; and wherein the method is effective to provide an enhanced CMI response against the or each expressed EOI in the host mammalian subject.

30

An advantage of this aspect of the present invention is the speed with which the method if capable of eliciting an enhanced CMI response. Prior techniques have generally required a

wait of at least about four weeks (about 28 days). In contrast, the present method typically requires between about 3-7 days following administration of an NOI. A further advantage of this aspect of the invention is the ability to enhance the CMI response without the use of an associated biological response modifier and/or an adjuvants in order to measure the  
5 enhancement of the CMI response.

In another aspect, there is provided an activated T-cell obtainable by the method or process of the present invention.

10 Numerous potential uses of activated T-cells are envisioned. For example, in the case of human therapy, it is contemplated that activated T-cells may be isolated, cultured *ex vivo* and administered to a host subject for the treatment of T cell mediated immune disorders and/or viral infections or patients with cancer. In accordance with this aspect of the invention, the T-cells are prepared by administering the NOI *in vivo* and then isolating the  
15 T-cells to expand *in vitro* in the presence of appropriate biological response modifiers and/or immunomodulators and/or adjuvants such as but not limited to peptide, cytokines and presenting cells.

The present invention also provides assay methods for the rapid and sensitive screening of a  
20 large number of candidate agents capable of specifically enhancing or modulating an enhanced CMI response, and which are therefore most appropriate for use in prophylactic and/or therapeutic and/or immunotherapeutic compositions to elicit and/or modulate an enhanced CMI response. An advantage of this aspect of the present invention is the speed with which the ability of the candidate agent to elicit and/or modulate an enhanced CMI  
25 response can be determined. Prior techniques have generally required a wait of at least four weeks (ie about 28 days). In contrast, the present technique typically requires between about 3-7 days following administration of an NOI encoding a candidate agent. A further advantage of this aspect of the invention is the ability to test for T-cell inducing/enhancing and/or modulating candidate agents without the use of an associated biological response  
30 modifier and/or an adjuvants in order to measure the enhancement of the CMI response in terms of T-cell activity.

In another aspect, there is provided an identified candidate agent for use either alone or in prophylactic and/or therapeutic and/or immunotherapeutic compositions to induce and/or modulate an enhanced CMI response or a T cell mediated immune disorder.

5 In a further aspect, there is provided a method of selectively eliciting an enhanced humoral response without necessarily eliciting an associated enhancement of the CMI response wherein the method comprises administration of an NOI encoding one or more EOIs of a TA at least three times to the host subject wherein the time interval between each NOI administration is about 48 hours and wherein the method is effective to provide an  
10 enhanced humoral immune response against the or each expressed EOI in the host mammalian subject.

In another aspect, there is provide a method of eliciting an enhanced humoral response wherein the method comprises administration of an NOI encoding one or more EOIs of a  
15 TA at least three times to the host subject wherein the time interval between each NOI administration is about 28 days and wherein the method is effective to provide an enhanced CMI response that helps to enhance the humoral immune response against the or each expressed EOI in the host mammalian subject.

20 PREFERRED ASPECTS

The NOI that is used to enhance the CMI response includes but is not limited to a DNA sequence under the control of a regulatory sequence which directs the expression of the DNA sequence in a mammalian host cell. In preferred embodiments, the T cell epitope may be from a helper T cell and/or a CD8+ T lymphocyte (CD8+ T cell). Even more  
25 preferably, the CMI response may be a CD8+ T lymphocyte response, such as a cytotoxic response.

Preferably, the NOI is administered about four times to the host subject.

30 Typically about 1 pg to about 5 mg of NOI provided to the subject in each administration (or at each time point), preferably from about 10 pg to about 100 ug, such 25 pg to 1 ug or 50 pg to about 500 pg.

Even more preferably, the NOI is administered as a double dose.

In the administration regimen the NOI is generally administered 2 to 5 times (at 2 to 5 different time points), such as 2, 3 or 4 times (at 2, 3 or 4 different time points respectively). Typically such administrations are over 2 to 14 days, for example over 4 to 12 or 6 to 10 days. In a preferred embodiment NOI at least 2, 3 or 4 administrations of NOI are carried out which may be separated by 3 days or less, such as 2 days or less. In one embodiment the time between the first and second administrations is less than 4 days, 10 typically less than 3.5 days, such as 3 days or less, or 2 days or less.

Preferably NOI is not administered to the subject in-between the administrations discussed herein, and typically other products which may stimulate an immune response (such as a polypeptide antigen), are not administered in-between the said NOI administrations. In one embodiment NOI, or another product which may stimulate an immune response (such as a polypeptide antigen), is not administered to the subject at least 7 days, such as at least 14 or at least 28 days before the first administration of NOI in any of the administration regimens mentioned herein. In one embodiment NOI, or another product which may stimulate an immune response (such as a polypeptide antigen), is not administered to the subject at least 20 7 days, such as at least 14 or at least 28 days after the last administration of NOI in any of the administration regimens mentioned herein.

For some embodiments, the NOI is co-administered with an adjuvant or an NOI encoding same. In this embodiment, the adjuvant is preferably the non-toxic form of the *E.coli* heat-labile enterotoxin (LT) or the *Vibrio Cholerae* cholera toxin (CT). Even more preferably, the adjuvant is the B subunit of the LT enterotoxin (LTB) or the B subunit of the CT Cholera toxin (CTB).

The inclusion of an adjuvant and in particular, a genetic adjuvant is useful in further 30 enhancing or modulating the CMI response. Thus the methods or processes of the present invention for enhancing a CMI response may be refined, by the addition of adjuvants to the

NOI or compositions comprising the NOI which lead to particularly effective compositions and methods for eliciting a long lived and sustained enhanced CMI response.

The NOI is preferably administered as a particle. In a preferred embodiment of the method

5 or process of the present invention, the NOI is administered transdermally. In an even more preferred embodiment, the particle is administered to the host mammalian subject by a particle acceleration device.

In one embodiment after the administration regimen has been carried out, whether or not

10 the regimen has led to the stimulation of a CMI (such as a CTL response) is ascertained. This can be done for example by measuring the presence of, or the level of, T cells (such as CTL) in a sample from the subject. The T cells which are detected are generally specific to an epitope encoded by the NOI.

15 Other aspects of the present invention are presented in the accompanying claims and in the following description and drawings. These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section are not necessarily limited to that particular section heading.

## 20 DEFINITIONS

Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified molecules or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be

25 limiting. In addition, the practice of the present invention will employ, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology, recombinant DNA techniques and immunology all of which are within the ordinary skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *DNA Cloning: A Practical Approach*, vol. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed., 1984); *A Practical Guide to Molecular Cloning* (1984); and *Fundamental Virology*, 2nd Edition, vol. 30 I & II (B.N. Fields and D.M. Knipe, eds.).

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety. It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.

## 10 IMMUNE RESPONSE

The mechanism by which the immune system controls disease includes the induction of neutralising antibodies via humoral immunity and the generation of T-cell responses via cellular immunity. As used herein, the term "immune response" against a target antigen (TA) refers to the development in a host mammalian subject of a humoral and/or a cellular immune response against that TA.

As used herein, the term "humoral immune response" refers to an immune response mediated by antibody molecules. The antibodies generated by humoral immunity are primarily effective against extracellular infectious agents.

20

As used herein, the term "cell mediated immune (CMI) response" is one mediated by T-lymphocytes and/or other white blood cells. The CMI immune mechanisms are generally more effective against intracellular infections and disease because the CMI mechanisms prime T cells in a way that, when a TA appears at a later date, memory T cells are activated to result in a CMI response that destroys target cells that have the corresponding TA or a portion thereof on their cell surfaces, and thereby the infecting pathogen. The CMI response is focused on the destruction of the source of infection mediated by either effector cells that destroy infected cells of the host by direct cell-to-cell contact and/or by the release of molecules, such as cytokines, that possess anti-viral activity. Thus the CMI response, which is characterised by a specific T lymphocyte cellular response, is crucial to produce resistance to diseases caused by cancer, viruses, pathogenic and other intracellular microorganisms.

## T CELLS IMPLICATED IN THE CMI RESPONSE

At least two special types of T cells are required to initiate and/or to enhance CMI and humoral responses. The antigenic receptors on a particular subset of T cells which express

5 a CD4 co-receptor can be T helper (Th) cells or CD4 T cells (herein after called T helper cells) and they recognise antigenic peptides bound to MHC class II molecules. In contrast, the antigenic receptors on a particular subset of T cells which express a CD8 co-receptor are called Cytotoxic T lymphocytes (CTLs) or CD8+ T cells (hereinafter called CD8+ T cells) and they react with antigens displayed on MHC Class I molecules.

10

### HELPER T CELLS

Helper T cells or CD4+ cells can be further divided into two functionally distinct subsets:

Th1 and Th2 which differ in their cytokine and effector function. Th1 and Th2 responses have been shown to be regulated not only in a positive but also in a negative way such that

15 Th1 cellular responses are augmented by Th1 cytokines such as IL-2, IL-12 and IFN-gamma and decreased by Th2 cytokines such as IL-4 and IL-10. In contrast, antibody responses are enhanced by Th2 cytokines such as IL-4 and IL-10 but are downregulated by Th1 cytokines such as IFN-gamma and another cytokine IL-12 that enhances IFN-gamma and is produced by monocytes. Thus, classic Th1 cytokines such as IFN-gamma, IL-2 and

20 IL-12 can be regarded as immune co-factors that induce an effective inflammatory response. In contrast, the classic Th2 cytokines such as IL-4 and IL-10 can be regarded as cytokines that will suppress a severe inflammatory response.

### CD8+ T CELLS

25 CD8+ T cells may function in more than one way. The best known function of CD8+ T cells is the killing or lysis of target cells bearing peptide antigen in the context of an MHC class I molecule. Hence the reason why these cells are often termed cytotoxic T lymphocytes (CTL). However, another function, perhaps of greater protective relevance in certain infections is the ability of CD8+ T cells to secrete interferon gamma (IFN-gamma).

30 Thus assays of lytic activity and of IFN-gamma release are both of value in measuring CD8+ T cell immune response (eg in an ELISPOT assay as set forth below). In infectious diseases there is evidence to suggest that CD8+ T cells can protect by killing an infectious

agent comprising an infectious antigen at the early stages of a disease before any symptoms of disease are produced.

#### ENHANCED CMI RESPONSE

5 The present invention concerns methods, processes and compositions capable of enhancing and/or modulating the CMI response in a host subject against a target antigen. As used herein, the term "enhancing" encompasses improvements in all aspects of the CMI response which include but are not limited to a stimulation and/or augmentation and/or potentiation and/or up-regulation of the magnitude and/or duration, and/or quality of the

10 CMI response to a repeatedly administered NOI encoding an EOI of a TA. By way of example, the CMI response may be enhanced by either (i) enhancing the activation and/or production and/or proliferation of CD8<sup>+</sup> T cells that recognise a target antigen and/or (ii) shifting the CMI response from a Th2 to a Th1 type response. This enhancement of the Th1 associated responses is of particular value in responding to intracellular infections because,

15 as explained above, the CMI response is enhanced by activated Th1 (such as, for example, IFN-gamma inducing) cells.

Such an enhanced immune response may be generally characterized by increased titers of interferon-producing CD4<sup>+</sup> and/or CD8<sup>+</sup> T lymphocytes, increased antigen-specific CD8<sup>+</sup> T cell activity, and a T helper 1-like immune response (Th1) against the antigen of interest (characterized by increased antigen-specific antibody titers of the subclasses typically associated with cellular immunity (such as, for example IgG2a), usually with a concomitant reduction of antibody titers of the subclasses typically associated with humoral immunity (such as, for example IgG1)) instead of a T helper 2-like immune response (Th2).

25 The enhancement of a CMI response may be determined by a number of well-known assays, such as by lymphoproliferation (lymphocyte activation) assays, CD8<sup>+</sup> T cell assays, or by assaying for T-lymphocytes specific for the epitope in a sensitized subject (see, for example, Erickson *et al.* (1993) *J. Immunol.* 151: 4189-4199; and Doe *et al.* (1994) *Eur. J. Immunol.* 24: 2369-2376) or CD8<sup>+</sup> T cell ELISPOT assays for measuring Interferon gamma production (Miyahara *et al.* *PNAS(USA)* (1998) 95: 3954-3959).

### ENHANCED T-CELL RESPONSE

As used herein, the term "enhancing a T-cell response" encompasses improvements in all aspects of the T-cell response which include but are not limited to a stimulation and/or augmentation and/or potentiation and/or up-regulation of the magnitude and/or duration, 5 and/or quality of the T-cell response to a repeatedly administered NOI encoding an EOI of a target antigen. By way of example, the T-cell response may be enhanced by either enhancing the activation and/or production and/or distribution and/or proliferation of the induced T-cells and/or longevity of the T-cell response to T-cell inducing/modulating NOIs encoding EOIs from a TA. The enhancement of the T-cell response in a host subject may 10 be associated with the enhancement and/or modulation of the Th1 immune response in the host subject.

The enhancement of the T-cell response may be determined by a number of well-known assays, such as by lymphoproliferation (lymphocyte activation) assays, CD8+ T-cell 15 cytotoxic cell assays, or by assaying for T-lymphocytes specific for the epitope in a sensitized subject (see, for example, Erickson *et al.* (1993) *J. Immunol.* 151: 4189-4199; and Doe *et al.* (1994) *Eur. J. Immunol.* 24: 2369-2376) or CD8+ T-cell ELISPOT assays for measuring Interferon gamma production (Miyahara *et al* PNAS(USA) (1998) 95: 3954-3959).

20

### ANTIGEN

Each disease causing agent or disease state has associated with it an antigen or immunodominant epitope on the antigen which is crucial in immune recognition and ultimate elimination or control of a disease causing agent or disease state in a host. In order 25 to mount a humoral and/or cellular immune response against a particular disease, the host immune system must come in contact with an antigen or an immunodominant epitope on an antigen associated with that disease state.

As used herein, the term "antigen" refers to any agent, generally a macromolecule, which 30 can elicit an immunological response in an individual. The immunological response may be of B- and/or T-lymphocytic cells. The term may be used to refer to an individual macromolecule or to a homogeneous or heterogeneous population of antigenic

macromolecules. As used herein, "antigen" is used to refer to a protein molecule or portion thereof which contains one or more antigenic determinants or epitopes.

#### TARGET ANTIGEN

5 As used herein, the term "target antigen (TA)" means an immunogenic peptide or protein of interest comprising one or more epitopes capable of inducing a CMI response to an infectious pathogen such as but not limited to a bacteria, viruses, fungi, yeast, parasites and other microorganisms capable of infecting mammalian species. The target antigen can include but is not limited to an auto-antigen, a self-antigen, a cross-reacting antigen, an  
10 alloantigen, a tolerogen, an allergen, a hapten, an immunogen or parts thereof as well as any combinations thereof.

#### EPITOPE

As used herein, the term "epitope" generally refers to the site on a target antigen which is  
15 recognised by a T-cell receptor and/or an antibody. Preferably it is a short peptide derived from or as part of a protein antigen. However the term is also intended to include peptides with glycopeptides and carbohydrate epitopes. Several different epitopes may be carried by a single antigenic molecule. The term "epitope" also includes modified sequences of amino acids or carbohydrates which stimulate responses which recognise the whole organism. It  
20 is advantageous if the selected epitope is an epitope of an infectious agent (such as a bacterium or virus) which causes the infectious disease. As used herein, the term epitope of interest (EOI) refers to one of more EOI which may be used in the methods or processes of the present invention.

#### 25 SOURCE OF EPITOPEs

The EOI can be generated from knowledge the amino acid and corresponding DNA sequences of the peptide or polypeptide, as well as from the nature of particular amino acids (e.g., size, charge, etc.) and the codon dictionary, without undue experimentation. See, e.g., Ivan Roitt, Essential Immunology, 1988; Kendrew, *supra*; Janis Kuby,  
30 Immunology, 1992 e.g., pp. 79-81. Some guidelines in determining whether a protein is an epitopes of interest which will stimulate a response, include: Peptide length--the peptide should be at least 8 or 9 amino acids long to fit into the MHC class I complex and at least

13-25 amino acids long to fit into a class II MHC complex. This length is a minimum for the peptide to bind to the MHC complex. It is preferred for the peptides to be longer than these lengths because cells may cut peptides. The peptide should contain an appropriate anchor motif which will enable it to bind to the various class I or class II molecules with 5 high enough specificity to generate an immune response (See Bocchia, M. et al, Specific Binding of Leukemia Oncogene Fusion Protein Pentides to HLA Class I Molecules, *Blood* 85:2680-2684; Englehard, VH, Structure of peptides associated with class I and class II MHC molecules *Ann. Rev. Immunol.* 12:181 (1994)). This can be done, without undue experimentation, by comparing the sequence of the protein of interest with published 10 structures of peptides associated with the MHC molecules. Thus, the skilled artisan can ascertain an epitope of interest by comparing the protein sequence with sequences listed in the protein data base.

The methods and processes of the present invention are generally applicable to enhancing 15 the CMI response against NOIs encoding EOIs from any source, including those from a wide variety of infectious agents such as viruses or parasites. By way of example, the EOI may be derived from pathogenic agents derived from tumour cells which multiply unrestrictedly in an organism and may thus lead to pathological growths. Examples of such pathogenic agents are described in Davis, B.D. *et al* (Microbiology, 3rd ed., Harper 20 International Edition). However, in preferred embodiments, the invention is exemplified by enhancing the CMI response against components of the HIV viral family. Enhanced CMI responses may be generated against EOIs located within the products of any viral gene, such as, for example, the gag, pol, nef and env genes, with the products of the env genes being preferred targets. Thus in one embodiment the method of the invention elicits an 25 immune response against particular antigens for the treatment and/or prevention of HIV infection and/or any condition which is caused by or exacerbated by HIV infection, such as AIDS.

#### T CELL EPITOPES

30 In the methods or processes of the present invention, the EOI of the TA may contain one or more T cell epitopes. As used herein, the term "T cell epitope" refers generally to those features of a peptide structure which are capable of inducing a T cell response. In this

regard, it is accepted in the art that T cell epitopes comprise linear peptide determinants that assume extended conformations within the peptide-binding cleft of MHC molecules (Unanue *et al.* (1987) *Science* 236: 551-557). As used herein, a T cell epitope is generally a peptide having at least about 3-5 amino acid residues, and preferably at least 5-10 or more 5 amino acid residues. However, as used herein, the term "T cell epitope" encompasses any MHC Class I-or MHC Class II restricted peptide. The ability of a particular T cell epitope to stimulate/enhance a CMI response may be determined by a number of well-known assays, such as by lymphoproliferation (lymphocyte activation) assays, CD8+ T-cell cytotoxic cell assays, or by assaying for T-lymphocytes specific for the epitope in a 10 sensitized subject. See, e. g., Erickson *et al.* (1993) *J. Immunol.* 151: 4189-4199; and Doe *et al.* (1994) *Eur. J. Immunol.* 24: 2369-2376 or CD8+ T-cell ELISPOT assays for measuring Interferon gamma production (Miyahara *et al* PNAS(USA) (1998) 95: 3954-3959).

15 CD8+ T-CELL EPITOPES

Preferably the EOI is a CD8+ T-cell EOI. A CD8+ T-cell -inducing EOI is an epitope capable of stimulating the formation, or increasing the activity, of specific CD8+ T-cells following its administration to a host subject. The CD8+ T-cell epitopes may be provided in a variety of different forms such as a recombinant string of one or two or more epitopes. 20 CD8+ T-cell epitopes have been identified and can be found in the literature, for many different diseases. It is possible to design epitope strings to generate CD8+ T-cell response against any chosen TA that contains such CD8+ T-cell EOIs. Advantageously, CD8+ T-cell EOIs may be provided in a string of multiple EOIs which are linked together without intervening sequences so that unnecessary nucleic acid material is avoided.

25

T HELPER EPITOPES

Preferably the EOI is a helper T lymphocyte EOI. Various methods are available to identify T helper cell EOIs suitable for use in accordance herewith. For example, the amphipathicity of a peptide sequence is known to effect its ability to function as a T helper 30 cell inducer. A full discussion of T helper cell-inducing epitopes is given in U.S. Patent 5,128,319, incorporated herein by reference.

## B CELL EPITOPES

Preferably the EOI is a mixture of CD8+ T-cell EOIs and B cell EOIs. As used herein, the term "B cell epitope" generally refers to the site on a TA to which a specific antibody molecule binds. The identification of epitopes which are able to elicit an antibody response 5 is readily accomplished using techniques well known in the art. See, e. g., Geysen *et al.* (1984) Proc. Natl. Acad. Sci. USA 81: 3998-4002 (general method of rapidly synthesizing peptides to determine the location of immunogenic epitopes in a given antigen); U. S. Patent No. 4,708,871 (procedures for identifying and chemically synthesizing epitopes of antigens); and Geysen *et al.* (1986) Molecular Immunology 23: 709-715 (technique for 10 identifying peptides with high affinity for a given antibody).

## COMBINATION OF EPITOPES

In a preferred embodiment of the present invention, the EOI is a mixture of a CD8+ T-cell - inducing EOI and a T helper cell-inducing EOI.

15

As is well known in the art, T and B cell inducing epitopes are frequently distinct from each other and can comprise different peptide sequences. Therefore certain regions of a protein's peptide chain can possess either T cell or B cell epitopes. Therefore, in addition to the CD8+ T-cell epitopes, it may be preferable to include one or more epitopes recognised by T 20 helper cells, to augment the immune response generated by the CD8+ T-cell epitopes.

The mechanism of enhancing a CD8+ T-cell induced response *in vivo* by T helper cell inducing agents is not completely clear. However, without being bound by theory, it is likely that the enhancing agent, by virtue of its ability to induce T helper cells, will result in increased levels of necessary cytokines that assist in the clonal expansion and dissemination 25 of specific CD8+ T-cells. Regardless of the underlying mechanism, it is envisioned that the use of mixtures of helper T cell and CD8+ T-cell -inducing EOIs in the methods or processes of the present invention will assist in the enhancement of the CMI response. Particularly suitable T helper cell epitopes are ones which are active in individuals of different HLA types, for example T helper epitopes from tetanus (against which most 30 individuals will already be primed). It may also be useful to include B cell EOIs for stimulating B cell responses and antibody production. Synthetic NOIs may also be

constructed to produce two types of immune responses: T cell only and T cell combined with a B cell response.

#### IMMUNODOMINANT EPITOPE

5 When an individual is immunized with an NOI encoding multiple EOIs of a TA, in many instances the majority of responding T lymphocytes will be specific for one or more linear EOIs from that TA and/or a majority of the responding B lymphocytes will be specific for one or more linear or conformational EOIs from that TA. For the purposes of the present invention, then, such EOIs are referred to as "immunodominant epitopes". In an antigen  
10 having several immunodominant EOIs a single EOI may be the most dominant in terms of commanding a specific T or B cell response.

Preferably the method or process of the present invention is effective in enhancing a CMI response against one or more HSV-2 epitopes.

15 Preferably the method or process of the present invention is effective in enhancing a CMI response against one or more immunodominant HSV-2 epitopes.

20 Preferably the method of the present invention is effective in generating/enhancing a CMI response against one or more HbsAg epitopes.

Preferably the method of the present invention is effective in generating/enhancing a CMI response against one or more immunodominant HbsAg epitopes.

25 As the Examples show, the enhanced CMI response obtained against both HSV-2 and HbsAg EOIs indicates that the methods or processes of the present invention are generally effective against EOI from diverse infectious pathogens. Moreover the protective effect against viral challenge indicates that the generation of a strong CD8+ T-cell response is of value in the development of preventative and therapeutic vaccination strategies.

30 Preferably the methods or processes of the present invention are effective in eliciting an enhanced CMI response against one or more EOIs associated with a tumour associated

antigen (TAA). Advantageously, EOIs derived from tumour associated antigens (TAA) can serve as targets for the host immune system and elicit responses which result in tumour destruction. Examples of such TAAs include but are not limited to MART-1 (Melanoma Antigen Recognised by T cells-1) MAGE-1, MAGE-3, 5T4, gp100, Carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), MUCIN (MUC-1), tyrosinase. Other TAAs may be identified, isolated and cloned by methods known in the art such as those disclosed in U.S. Patent No. 4,514,506.

10 In a preferred embodiment the NOI encodes at least two HIV antigens. The NOI may comprise a sequence encoding HIV gag protein, or fragment thereof containing an epitope, and one or more further HIV antigens or fragment thereof containing an epitope. The antigens may derive from any available HIV isolates (typically HIV-1), such as HXB2. The antigens may include gag antigens (or fragments thereof which contain an epitope) such as p24gag and p55gag, as well as proteins derived from the pol, env, tat, vif, rev, nef, 15 vpr, vpu and LTR regions of HIV (or fragments thereof which contain an epitope).

20 In a more preferred embodiment the NOI encodes at least three HIV antigens, preferably Gag, nef and RT (or instead of the whole protein a fragment of any of these proteins which contains an epitope). These coding sequences may be in any order, but are preferably in the order Nef-RT-Gag, RT-Nef, Gag or RT-Gag-Nef.

25 In one embodiment the HIV epitopes/proteins which are expressed are fusion proteins, such as a fusion protein containing sequence from (including the above-mentioned fragments) Nef, RT and Gag.

In a preferred embodiment, the gag gene does not encode the gag p6 peptide. Preferably the nef gene in the NOI is truncated to remove the sequence encoding the N terminal 81 amino acids.

30 The fragments of gag, or any other HIV antigen (such as nef or RT), which are encoded by the NOI generally comprise an epitope. The proteins (including said fragments) encoded by the NOI are generally at least 8 amino acids long, for example 8-10 amino acids or up to

20, 50, 60, 70, 80, 100, 150 or 200 amino acids in length. Any such protein may be codon optimised, e.g. such that the fragment has a codon usage pattern which resembles that of a highly expressed mammalian gene.

- 5     In one embodiment the NOI encodes one of the following combinations of polypeptide:
  - I.     p17, p24, fused to truncated NEF (devoid of nucleotides encoding terminal amino-acids 1-85).
  - II.    p17, p24, RT, truncated NEF (devoid of nucleotides encoding terminal amino-acids 1-85).
- 10    III.   p17, p24 (optimised gag) truncated NEF (devoid of nucleotides encoding terminal amino-acids 1-85).
- 15    IV.    p17, p24 (optimised gag) RT (optimised) truncated NEF (devoid of nucleotides encoding terminal amino-acids 1-85).
- 15    V.     p17, p24, RT (optimised) truncated NEF (devoid of nucleotides encoding terminal amino-acids 1-85).

In a preferred embodiment the NOI comprises any one or more of the polynucleotide sequences shown in Figures 18 to 22 or a fragment of such a sequence which encodes at least one epitope (preferably T cell epitope); or a homologue of any of the sequences of Figures 18 to 22 or a homologue of said fragment. Such a fragment or homologue is typically at least 50 nucleotides, such as at least 100, 200, 500 or 1000 nucleotides in length. In one embodiment the NOI is in the form of a plasmid as shown in any one of Figures 17 or 20 to 22 or a fragment or derivative (including a homologue) of such a plasmid. The construction of the plasmids is described in WO 03/080112 (incorporated herein by reference).

#### OPTIMISED CODONS

In a preferred embodiment of the invention the coding sequence of the NOI is optimised to resemble the codon usage of highly expressed genes in mammalian cells. The DNA code has 4 letters (A, T, C and G) and uses these to spell three letter "codons" which represent the amino acids the proteins encoded in an organism's genes. The linear sequence of codons along the DNA molecule is translated into the linear sequence of amino acids in the

protein(s) encoded by those genes. The code is highly degenerate, with 61 codons coding for the 20 natural amino acids and 3 codons representing "stop" signals. Thus, most amino acids are coded for by more than one codon - in fact several are coded for by four or more different codons.

5

Where more than one codon is available to code for a given amino acid, it has been observed that the codon usage patterns of organisms are highly non-random. Different species show a different bias in their codon selection and, furthermore, utilization of codons may be markedly different in a single species between genes which are expressed at high 10 and low levels. This bias is different in viruses, plants, bacteria and mammalian cells, and some species show a stronger bias away from a random codon selection than others.

For example, humans and other mammals are less strongly biased than certain bacteria or viruses. For these reasons, there is a significant probability that a mammalian gene 15 expressed in E.coli or a viral gene expressed in mammalian cells will have an inappropriate distribution of codons for efficient expression. It is believed that the presence in a heterologous DNA sequence of clusters of codons which are rarely observed in the host in which expression is to occur, is predictive of low heterologous expression levels in that host.

20

In the NOI, the codon usage pattern may be altered from that found naturally to more closely represent the codon bias of the target organism, e.g. a mammal, especially a human. The "codon usage coefficient" is a measure of how closely the codon pattern of a given 25 polynucleotide sequence resembles that of a target species. Codon frequencies can be derived from literature sources for the highly expressed genes of many species (see e.g. Nakamura et.al. Nucleic Acids Research 1996, 24:214-215). The codon frequencies for each of the 61 codons (expressed as the number of occurrences occurrence per 1000 codons of the selected class of genes) are normalised for each of the twenty natural amino acids, so that the value for the most frequently used codon for each amino acid is set to 1 and the 30 frequencies for the less common codons are scaled to lie between zero and 1. Thus each of the 61 codons is assigned a value of 1 or lower for the highly expressed genes of the target species. In order to calculate a codon usage coefficient for a specific polynucleotide,

relative to the highly expressed genes of that species, the scaled value for each codon of the specific polynucleotide are noted and the geometric mean of all these values is taken (by dividing the sum of the natural logs of these values by the total number of codons and take the anti-log). The coefficient will have a value between zero and 1 and the higher the

5 coefficient the more codons in the polynucleotide are frequently used codons. If a polynucleotide sequence has a codon usage coefficient of 1, all of the codons are "most frequent" codons for highly expressed genes of the target species.

According to the present invention, the codon usage pattern of the NOI will preferably

10 exclude codons with an RSCU value of less than 0.2 in highly expressed genes of the target organism. A relative synonymous codon usage (RSCU) value is the observed number of codons divided by the number expected if all codons for that amino acid were used equally frequently. The NOI will generally have a codon usage coefficient for highly expressed human genes of greater than 0.3, preferably greater than 0.4, most preferably greater than  
 15 0.5. Codon usage tables for human can also be found in GenBank. In comparison, a highly expressed beta action gene has a RSCU of 0.747. The codon usage table for a homo sapiens is set out below:

***Homo sapiens [gbpri]: 27143 CDS's (12816923 codons)***

fields: [triplet] [frequency: per thousand] ([number])

20	UUU 17.0 (217684)	UCU 14.8 (189419)	UAU 12.1 (155645)	UGU 10.0 (127719)
	UUC 20.5 (262753)	UCC 17.5 (224470)	UAC 15.8 (202481)	UGC 12.3 (157257)
	UUA 7.3 ( 93924)	UCA 11.9 (152074)	UAA 0.7 ( 9195)	UGA 1.3 ( 16025)
	UUG 12.5 (159611)	UCG 4.5 ( 57572)	UAG 0.5 ( 6789)	UGG 12.9 (165930)
25	CUU 12.8 (163707)	CCU 17.3 (222146)	CAU 10.5 (134186)	CGU 4.6 ( 59454)
	CUC 19.3 (247391)	CCC 20.0 (256235)	CAC 14.9 (190928)	CGC 10.8 (137865)
	CUA 7.0 ( 89078)	CCA 16.7 (214583)	CAA 12.0 (153590)	CGA 6.3 ( 80709)
	CUG 39.7 (509096)	CCG 7.0 ( 89619)	CAG 34.5 (441727)	CGG 11.6 (148666)
30	AUU 15.8 (202844)	ACU 12.9 (165392)	AAU 17.0 (218508)	AGU 12.0 (154442)
	AUC 21.6 (277066)	ACC 19.3 (247805)	AAC 19.8 (253475)	AGC 19.3 (247583)
	AUA 7.2 ( 92133)	ACA 14.9 (191518)	AAA 24.0 (308123)	AGA 11.5 (147264)
	AUG 22.3 (285776)	ACG 6.3 ( 80369)	AAG 32.6 (418141)	AGG 11.3 (145276)
35	GUU 10.9 (139611)	GCU 18.5 (236639)	GAU 22.4 (286742)	GGU 10.8 (138606)
	GUC 14.6 (187333)	GCC 28.3 (362086)	GAC 26.1 (334158)	GGC 22.7 (290904)
	GUA 7.0 ( 89644)	GCA 15.9 (203310)	GAA 29.1 (373151)	GGA 16.4 (210643)
	GUG 28.8 (369006)	GCG 7.5 ( 96455)	GAG 40.2 (515485)	GGG 16.4 (209907)

Coding GC 52.51% 1st letter GC 56.04% 2nd letter GC 42.35% 3rd letter GC 59.13%

## ADJUVANTS

5 The method or process of the present invention does not require the presence of an adjuvant to demonstrate an enhanced CMI response. However, the inclusion of an adjuvant and in particular, a genetic adjuvant may be useful in further enhancing or modulating the CMI response. An adjuvant may enhance the CMI response by enhancing the immunogenicity of a co-administered antigen in an immunized subject, as well inducing a Th1-like immune

10 response against the co-administered antigen which is beneficial in a vaccine product.

Thus the methods or processes of the present invention for enhancing a CMI response may be refined, by the addition of adjuvants to the NOI or compositions comprising the NOI which lead to particularly effective compositions and methods for eliciting a long lived and

15 sustained enhanced CMI response.

As used herein, the term "adjuvant" refers to any material or composition capable of specifically or non-specifically altering, enhancing, directing, redirecting, potentiating or initiating an antigen-specific immune response.

20 The term "adjuvant" includes but is not limited to a bacterial ADP-ribosylating exotoxin, a biologically active factor, immunomodulatory molecule, biological response modifier or immunostimulatory molecule such as a cytokine, an interleukin, a chemokine or a ligand or an epitope (such as a helper T cell epitope) and optimally combinations thereof which, 25 when administered with the NOI enhances or potentiates or modulates the CMI response relative to the CMI response generated upon administration of the NOI alone. The adjuvant may be any adjuvant known in the art which is appropriate for human or animal use.

30 Immunomodulatory molecules such as cytokines (TNF-alpha, IL-6, GM-CSF, and IL-2), and co-stimulatory and accessory molecules (B7-1, B7-2) may be used as adjuvants in a variety of combinations. In one embodiment GM-CSF is not administered to subject before, in or after the administration regimen. Simultaneous production of an

immunomodulatory molecule and an EOI at the site of expression of the EOI may enhance the generation of specific effectors which may help to enhance the CMI response. The degree of enhancement of the CMI response may be dependent upon the specific immunostimulatory molecules and/or adjuvants used because different immunostimulatory molecules may elicit different mechanisms for enhancing and/or modulating the CMI response. By way of example, the different effector mechanisms/immunomodulatory molecules include but are not limited to augmentation of help signal (IL-2), recruitment of professional APC (GM-CSF), increase in T cell frequency (IL-2), effect on antigen processing pathway and MHC expression (IFN-gamma and TNF-alpha) and diversion of immune response away from the Th1 response and towards a Th2 response (LTB) (see WO 97/02045). Unmethylated CpG containing oligonucleotides (see WO96/02555) are also preferential inducers of a Th1 response and are suitable for use in the present invention.

Without being bound by theory, the inclusion of an adjuvant is advantageous because the adjuvant may help to enhance the CMI response to the expressed NOI by diverting the Th2 response to a Th1 response and/or specific effector associated mechanisms to an expressed EOI with the consequent generation and maintenance of an enhanced CMI response (see, for example, the teachings in WO 97/02045).

The inclusion of an adjuvant with the NOI is also advantageous because it may result in a lower dose or fewer doses of NOI being necessary to achieve the desired CMI response in the subject to which the NOI is administered, or it may result in a qualitatively and/or quantitatively different immune response in the subject. The effectiveness of an adjuvant can be determined by administering the adjuvant with the NOI in parallel with the NOI alone to animals and comparing antibody and/or cellular-mediated immunity in the two groups using standard assays such as radioimmunoassay, ELISAs, CD8+ T-cell assays, and the like, all well known in the art. Typically, the adjuvant is a separate moiety from the antigen, although a single molecule can have both adjuvant and antigen properties.

As used herein, the term "genetic adjuvant" refers to an adjuvant encoded by an NOI and which, when administered with the NOI encoding the EOI of the present invention

enhances the CMI response relative to the CMI response generated upon administration of the NOI alone.

5 In one preferred embodiment, the genetic adjuvant is a bacterial ADP-ribosylating exotoxin.

10 ADP-ribosylating bacterial toxins are a family of related bacterial exotoxins and include diphtheria toxin (DT), pertussis toxin (PT), cholera toxin (CT), the *E. coli* heat-labile toxins (LT1 and LT2), *Pseudomonas* endotoxin A, *Pseudomonas* exotoxin S, *B. cereus* exoenzyme, *B. sphaericus* toxin, *C. botulinum* C2 and C3 toxins, *C. limosum* exoenzyme, as well as toxins from *C. perfringens*, *C. spiriforma* and *C. difficile*, *Staphylococcus aureus* EDIN, and ADP-ribosylating bacterial toxin mutants such as CRM<sub>197</sub>, a non-toxic diphtheria toxin mutant (see, e.g., Bixler et al. (1989) *Adv. Exp. Med. Biol.* 251:175; and Constantino et al. (1992) *Vaccine*). Most ADP-ribosylating bacterial toxins are organized 15 as an A:B multimer, wherein the A subunit contains the ADP-ribosyltransferase activity, and the B subunit acts as the binding moiety. Preferred ADP-ribosylating bacterial toxins for use in the compositions of the present invention include cholera toxin and the *E. coli* heat-labile toxins.

20 Cholera toxin (CT) and the related *E. coli* heat labile enterotoxins (LT) are secretion products of their respective enterotoxic bacterial strains that are potent immunogens and exhibit strong toxicity when administered systemically, orally, or mucosally. Both CT and LT are known to provide adjuvant effects for antigen when administered via the intramuscular or oral routes. These adjuvant effects have been observed at doses below 25 that required for toxicity. The two toxins are extremely similar molecules, and are at least about 70-80% homologous at the amino acid level.

30 Preferably the genetic adjuvant is cholera toxin (CT), enterotoxigenic *E. Coli* heat-labile toxin (LT), or a derivative, subunit, or fragment of CT or LT which retains adjuvanticity. In an even more preferred embodiment, the genetic adjuvant is LT. In another preferred embodiment, the genetic adjuvant may be CTB or LTB.

Preferably the enterotoxin is a non-toxic enterotoxin. By way of example, at least one of the enterotoxin subunit coding regions may be genetically modified to detoxify the subunit peptide encoded thereby, for example wherein the truncated A subunit coding region has been genetically modified to disrupt or inactivate ADP-ribosyl transferase activity in the 5 subunit peptide expression product (see WO 03/004055).

In the examples described below, the LT holotoxin comprising native A and B subunits expressed by a plasmid vector was used as a genetic adjuvant which was co-administered with the NOI expressing the HSV-2/HbsAg antigen to obtain an enhanced CMI response. 10 The results demonstrate that the inclusion of an adjuvant greatly improve the capability of eliciting a CMI response, in terms of generating a systemic T cell response compared to administration of an NOI without the adjuvant.

Thus, these results demonstrate that this genetic adjuvant is particularly desirable where an 15 even more enhanced CMI response is desired. Other desirable genetic adjuvants include but are not limited to NOI encoding IL-10, IL-12, IL-13, the interferons (IFNs) (for example, IFN-alpha, IFN-ss, and IFN-gamma), and preferred combinations thereof. Still other such biologically active factors that enhance the CMI response may be readily selected by one of skill in the art, and a suitable plasmid vector containing same constructed by known 20 techniques.

#### NOI

The EOIs of the present invention are administered as nucleotide sequences encoding the EOI. As used herein, the term nucleotide sequence of interest (NOI) refers to one or more 25 NOI which encode one or more EOIs which are used in the method or processes of the present invention. The NOI may also encode one or more candidate agent for testing in an assay method of the present invention. The term "nucleotide sequence of interest (NOI)" is synonymous with the term "polynucleotide". The NOI may be DNA or RNA of genomic or synthetic or of recombinant origin. The NOI may be double-stranded or single-stranded 30 whether representing the sense or antisense strand or combinations thereof. For some applications, preferably, the NOI is DNA. For some applications, preferably, the NOI is prepared by use of recombinant DNA techniques (e.g. recombinant DNA). For some

applications, preferably, the NOI is cDNA. For some applications, preferably, the NOI may be the same as the naturally occurring form.

## VECTOR

5 In one embodiment of the present invention, the NOI is administered directly to a host subject. In another embodiment of the present invention, a vector comprising an NOI is administered to a host subject. Preferably the NOI is prepared and/or administered using a genetic vector. As it is well known in the art, a vector is a tool that allows or facilitates the transfer of an entity from one environment to another. In accordance with the present 10 invention, and by way of example, some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a host and/or a target cell for the purpose of replicating the vectors comprising the NOI of the present invention and/or expressing the EOIs of the present invention encoded by the NOI. Examples of vectors 15 used in recombinant DNA techniques include but are not limited to plasmids, chromosomes, artificial chromosomes or viruses. The term "vector" includes expression vectors and/or transformation vectors. The term "expression vector" means a construct capable of *in vivo* or *in vitro/ex vivo* expression. The term "transformation vector" means a construct capable of being transferred from one species to another.

20

In one embodiment a viral promoter is used to drive expression from the NOI. The promoter may be a Cytomegalovirus (CMV) promoter. A preferred promoter element (particularly in the case where the NOI encodes an HIV antigen) is the CMV immediate early promoter devoid of intron A, but including exon 1. Thus the expression from the NOI 25 may be under the control of HCMV IE early promoter.

## NAKED DNA

The vectors comprising the NOI of the present invention may be administered directly as "a naked nucleic acid construct", preferably further comprising flanking sequences 30 homologous to the host cell genome. As used herein, the term "naked DNA" refers to a plasmid comprising the NOI of the present invention together with a short promoter region to control its production. It is called "naked" DNA because the plasmids are not carried in

any delivery vehicle. When such a DNA plasmid enters a host cell, such as a eukaryotic cell, the proteins it encodes are transcribed and translated within the cell.

### VIRAL VECTORS

5 Alternatively, the vectors comprising the NOI of the present invention may be introduced into suitable host cells using a variety of viral techniques which are known in the art, such as for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses. The vector may be a recombinant viral vectors. Suitable recombinant viral vectors include but are not limited to adenovirus vectors, adeno-  
10 associated viral (AAV) vectors, herpes-virus vectors, a retroviral vector, lentiviral vectors, baculoviral vectors, pox viral vectors or parvovirus vectors (see Kestler *et al* 1999 Human Gene Ther 10(10):1619-32). In the case of viral vectors, administration of the NOI is mediated by viral infection of a target cell.

15 TARGETED VECTOR

The term "targeted vector" refers to a vector whose ability to infect or transfet or transduce a cell or to be expressed in a host and/or target cell is restricted to certain cell types within the host subject, usually cells having a common or similar phenotype.

20 EXPRESSION VECTOR

Preferably, the NOI of the present invention which is inserted into a vector is operably linked to a control sequence that is capable of providing for the expression of the EOI, by the host cell, i.e. the vector is an expression vector. The agent produced by a host cell may be secreted or may be contained intracellularly depending on the NOI and/or the vector used. As will be understood by those of skill in the art, expression vectors containing the NOI can be designed with signal sequences which direct secretion of the EOI through a particular prokaryotic or eukaryotic cell membrane.

### FUSION PROTEINS

30 The NOI of the present invention may be expressed as a fusion protein comprising an adjuvant and/or a biological response modifier and/or immunomodulator fused to the EOI to further enhance and/or augment the CMI response obtained. The biological response

modifier may act as an adjuvant in the sense of providing a generalised stimulation of the CMI response. The EOI may be attached to either the amino or carboxy terminus of the biological response modifier.

## 5 NOI ADMINISTRATION

The NOI of the present invention may be administered, either alone or as part of a composition, via a variety of different routes. Certain routes may be favoured for certain compositions, as resulting in the generation of a more effective CMI response, or as being less likely to induce side effects, or as being easier for administration. The route of administration for a vaccine composition may vary depending upon the identity of the pathogen or infection to be prevented or treated.

The NOI of the present invention may be administered via a systemic route or a mucosal route or a transdermal route or it may be administered directly into a specific tissue such as the liver, bone marrow or into the tumour in the case of cancer therapy. As used herein, the term "systemic administration" includes but is not limited to any parenteral routes of administration. In particular, parenteral administration includes but is not limited to subcutaneous, intraperitoneal, intravenous, intraarterial, intramuscular, or intrasternal injection, intravenous, intraarterial, or kidney dialytic infusion techniques. Preferably, the systemic, parenteral administration is intramuscular injection.

In one preferred embodiment of the method, the NOI is administered via a transdermal route. While it is believed that any accepted mode and route of immunization can be employed and nevertheless achieve some advantages in accordance herewith, the examples below demonstrate particular advantages with transdermal NOI administration. In this regard, and without being bound by theory, it is believed that transdermal NOI administration is preferred because it more efficiently activates the cell mediated arm of the immune system.

The term "transdermal" delivery intends intradermal (e.g., into the dermis or epidermis), transdermal (e.g., "percutaneous") and transmucosal administration, i.e., delivery by passage of an agent into or through skin or mucosal tissue. *See, e.g., Transdermal Drug*

*Delivery: Developmental Issues and Research Initiatives*, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); *Controlled Drug Delivery: Fundamentals and Applications*, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and *Transdermal Delivery of Drugs*, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press, (1987). Thus, the term encompasses delivery of  
5 an agent using a particle delivery device (e.g., a needleless syringe) such as those described in U.S. Patent No. 5,630,796, as well as delivery using particle-mediated delivery devices such as those described in U.S. Patent No. 5,865,796.

As used herein, the term "mucosal administration" includes but is not limited to oral,  
10 intranasal, intravaginal, intrarectal, intratracheal, intestinal and ophthalmic administration.

Mucosal routes, particularly intranasal, intratracheal, and ophthalmic are preferred for protection against natural exposure to environmental pathogens such as RSV, flu virus and cold viruses or to allergens such as grass and ragweed pollens and house dust mites. The  
15 enhancement of the CMI response will enhance the protective effect against a subsequently encountered target antigen such as an allergen or microbial agent.

In another preferred embodiment of the present invention, the NOI may be administered to cells which have been isolated from the host subject. In this preferred embodiment,  
20 preferably the NOI encoding an EOI from a tumour associated antigen (TAA) is administered to professional antigen presenting cells (APCs), such as dendritic cells. APCs may be derived from a host subject and modified *ex vivo* to express an EOI and then transferred back into the host subject to induce an enhanced CMI response against the TAA in order to elicit an anti-tumour response. Dendritic cells are believed to be the most potent  
25 APCs for stimulating enhanced CMI responses because the expressed EOIs must be acquired, processed and presented by professional APCs to T cells (both Th1 and Th2 helper cells as well as CD8+ T-cells) in order to induce an enhanced CMI response. In an alternative embodiment, cancer cells from a host subject may be modified *in situ* or *in vitro*.

### 30 NOI PARTICLE ADMINISTRATION

Particle-mediated methods for delivering NOI preparations are known in the art. Thus, once prepared and suitably purified, the above-described NOIs can be coated onto core carrier

particles using a variety of techniques known in the art. Carrier particles are selected from materials which have a suitable density in the range of particle sizes typically used for intracellular delivery from a gene gun device. The optimum carrier particle size will, of course, depend on the diameter of the target cells.

5

By "core carrier"" is meant a carrier on which a guest nucleic acid (e.g., DNA, RNA) is coated in order to impart a defined particle size as well as a sufficiently high density to achieve the momentum required for cell membrane penetration, such that the guest molecule can be delivered using particle-mediated techniques (see, e.g., U.S. Patent No.

10 5,100,792). Core carriers typically include materials such as tungsten, gold, platinum, ferrite, polystyrene and latex. See e.g., *Particle Bombardment Technology for Gene Transfer*, (1994) Yang, N. ed., Oxford University Press, New York, NY pages 10-11. Tungsten and gold particles are preferred. Tungsten particles are readily available in average sizes of 0.5 to 2.0 microns in diameter. Gold particles or microcrystalline gold (e.

15 g., gold powder A1570, available from Engelhard Corp., East Newark, NJ) will also find use with the present invention. Gold particles provide uniformity in size (available from Alpha Chemicals in particle sizes of 1-3 microns, or available from Degussa, South Plainfield, NJ in a range of particle sizes including 0.95 microns). Microcrystalline gold provides a diverse particle size distribution, typically in the range of 0.5-5 microns.

20 However, the irregular surface area of microcrystalline gold provides for highly efficient coating with nucleic acids. A number of methods are known and have been described for coating or precipitating NOIs onto gold or tungsten particles. Most such methods generally combine a predetermined amount of gold or tungsten with plasmid DNA, CaCl<sub>2</sub> and spermidine. The resulting solution is vortexed continually during the coating procedure to

25 ensure uniformity of the reaction mixture. After precipitation of the NOI, the coated particles can be transferred to suitable membranes and allowed to dry prior to use, coated onto surfaces of a sample module or cassette, or loaded into a delivery cassette for use in particular gene gun instruments.

30 By "particle delivery device" is meant an instrument which delivers a particulate composition transdermally without the aid of a conventional needle to pierce the skin. Particle delivery devices for use with the present invention are discussed throughout this

document. Various particle acceleration devices suitable for particle-mediated delivery are known in the art, and are all suited for use in the practice of the invention. Current device designs employ an explosive, electric or gaseous discharge to propel the coated carrier particles toward target cells. The coated carrier particles can themselves be releasably attached to a movable carrier sheet, or removably attached to a surface along which a gas stream passes, lifting the particles from the surface and accelerating them toward the target. An example of a gaseous discharge device is described in U. S. Patent No. 5,204,253. An explosive-type device is described in U. S. Patent No. 4,945,050. One example of a helium discharge-type particle acceleration apparatus is the PowderJect XR instrument (PowderJect Vaccines, Inc., Madison), WI, which instrument is described in U. S. Patent No. 5,120,657. An electric discharge apparatus suitable for use herein is described in U. S. Patent No. 5,149,655. The disclosure of all of these patents is incorporated herein by reference. Alternatively, particulate NOIs compositions can administered transdermally using a needleless syringe device. For example, a particulate composition comprising the NOIs of the present invention can be obtained using general pharmaceutical methods such as simple evaporation (crystallization), vacuum drying, spray drying or lyophilization. If desired, the particles can be further densified using the techniques described in commonly owned International Publication No. WO 97/48485, incorporated herein by reference. These particulate compositions can then be delivered from a needleless syringe system such as those described in commonly owned International Publication Nos. WO 94/24263, WO 96/04947, WO 96/12513, and WO 96/20022, all of which are incorporated herein by reference. Delivery of particles comprising antigens or allergens from the above referenced needleless syringe systems is practiced with particles having an approximate size generally ranging from 0.1 to 250 microns, preferably ranging from about 10-70 microns. Particles larger than about 250 microns can also be delivered from the devices, with the upper limitation being the point at which the size of the particles would cause untoward damage to the skin cells. The actual distance which the delivered particles will penetrate a target surface depends upon particle size (e. g., the nominal particle diameter assuming a roughly spherical particle geometry), particle density, the initial velocity at which the particle impacts the surface, and the density and kinematic viscosity of the targeted skin tissue. In this regard, optimal particle densities for use in needleless injection generally range between about 0.1 and 25 g/cm<sup>3</sup>, preferably between about 0.9 and 1.5 g/cm<sup>3</sup>, and injection

velocities generally range between about 100 and 3,000 m/sec. With appropriate gas pressure, particles having an average diameter of 10-70 Rm can be accelerated through the nozzle at velocities approaching the supersonic speeds of a driving gas flow.

5 The particle compositions or coated particles are administered to the individual in a manner compatible with the dosage formulation, and in an amount that will be effective for the purposes of the invention. The amount of the composition to be delivered (e. g., about 0.1 mg to 1 mg, more preferably 1 to 50 ug of the antigen or allergen, depends on the individual to be tested. The exact amount necessary will vary depending on the age and  
10 general condition of the individual to be treated, and an appropriate effective amount can be readily determined by one of skill in the art upon reading the instant specification.

Gold or tungsten microparticles can also be used as transporting agents, as described in WO 93/17706, and Tang petal., *Nature* (1992)356:152. In this particular case, the NOI is  
15 precipitated on the microparticles in the presence of calcium chloride and spermidine, and then the whole is administered by a high-speed jet into the dermis or into the epidermis using an apparatus with no needle, such as those described in U.S. Patent Nos. 4,945,050 and 5,015,580, and WO 94/24243. The quantity of NOI that can be used to vaccinate a host subject depends on a number of factors such as, for example, the strength of the  
20 promoter used to express the antigen, the immunogenicity of the product expressed, the condition of the mammal for whom the administration is intended (e.g., the weight, age, and general state of health), the mode of administration, and the type of formulation. In general, an appropriate dose for prophylactic or therapeutic use in an adult of the human species is from about 1 pg to about 5 mg, preferably from about 10 pg to about 1 mg, most  
25 preferably from about 25 pg to about 500 pg. Particle-mediated delivery techniques have been compared to other types of NOI administration, and found markedly superior. Fynan *et al.* (1995) *Int. J. Immunopharmacology* 17:79-83, Fynan *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:11478-11482, and Raz *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:9519-9523. Such studies have investigated particle-mediated delivery of nucleic acid-based  
30 vaccines to both superficial skin and muscle tissue. One possible reason for the markedly better results achieved with the gene gun is that the NOI is delivered intracellularly as opposed to the extracellular delivery by intramuscular injection.

Preferably the interval between administration of the target antigen (TA) ranges from about 48 hours to about 192 hours

5 More preferably, the interval between administration of the target antigen (TA) ranges from about 72 hours to about 168 hours.

Even more preferably, the intervals between administration of the target antigen (TA) ranges from about 72 hours to about 144 hours.

10

#### HOST MAMMALIAN SUBJECT

As used herein, the term "host mammalian subject" means any member of the subphylum cordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as

15 cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The terms do not denote a particular age. Thus, both adult and newborn individuals are intended to be covered. The methods described herein are intended for use  
20 in any of the above vertebrate species, since the immune systems of all of these vertebrates operate similarly. If a mammal, the subject will preferably be a human, but may also be a domestic livestock, laboratory subject or pet animal.

#### PREVENT AND/OR TREAT

25 This method or process of the present invention is broadly applicable to vaccination methods and is relevant to the development of prophylactic and/or therapeutic vaccines (including immunotherapeutic vaccines). It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

30 In the method or process of the present invention, the NOI described herein may be employed alone as part of a composition, such as but not limited to a pharmaceutical composition or a vaccine composition or an immunotherapeutic composition to prevent

and/or treat a T cell mediated immune disorder. The administration of the NOI of the present invention or a composition comprising the NOI may be for either "prophylactic" or "therapeutic" purpose. As used herein, the term "therapeutic" or "treatment" includes any of following: the prevention of infection or reinfection; the reduction or elimination of 5 symptoms; and the reduction or complete elimination of a pathogen. Treatment may be effected prophylactically (prior to infection) or therapeutically (following infection).

Prophylaxis or therapy includes but is not limited to eliciting an effective CMI immune response to an NOI and/or alleviating, reducing, curing or at least partially arresting 10 symptoms and/or complications resulting from a T cell mediated immune disorder. When provided prophylactically, the composition of the present invention is typically provided in advance of any symptom. The prophylactic administration of the NOI or composition of the present invention is to prevent or ameliorate any subsequent infection or disease. When provided therapeutically, the NOI or composition of the present invention is typically 15 provided at (or shortly after) the onset of a symptom of infection or disease. Thus the composition of the present invention may be provided either prior to the anticipated exposure to a disease causing agent or disease state or after the initiation of an infection or disease.

20 Whether prophylactic or therapeutic NOI administration (either alone or as part of a composition) is the more appropriate will usually depend upon the nature of the disease. By way of example, the immunotherapeutic composition of the present invention could be used in immunotherapy protocols to actively inducing tumour immunity by vaccination with a tumour cell or its antigenic components. This latter form of treatment is 25 advantageous because the immunity is prolonged and because there is a general belief that one of the best ways to eliminate tumours would be to induce a strong specific anti-tumour CTL response. On the other hand a vaccine composition will preferably, though not necessarily be used prophylactically to induce an effective CMI response against subsequently encountered antigens or portions thereof (such as epitopes) related to the 30 target antigen.

**PROPHYLACTICALLY OR THERAPEUTICALLY EFFECTIVE AMOUNT**

The dose of NOI or composition comprising the NOI administrated to a host subject, in the context of the present invention, should be sufficient to effect a beneficial prophylactic or therapeutic CMI response in the subject over time.

5

As used herein, the term ““prophylactically or therapeutically effective dose” means a dose in an amount sufficient to elicit an enhanced CMI response to one or more EOIs of a specific target antigens and/or to alleviate, reduce, cure or at least partially arrest symptoms and/or complications from a T cell mediated immune disorder

10

**DOSAGE**

Prophylaxis or therapy can be accomplished by a single direct administration at a single time point or multiple time points. Administration can also be delivered to a single or to multiple sites. Some routes of administration, such as mucosal administration via 15 ophthalmic drops may require a higher dose. Those skilled in the art can adjust the dosage and concentration to suit the particular route of delivery. Advantageously, the Examples demonstrate that a single dose of the NOI or the composition comprising the NOI is usually sufficient to achieve an enhanced CMI response.

## T CELL MEDIATED IMMUNE DISORDERS

Because the method or process of the present invention elicits an enhanced CMI response, the method can be used to protect against subsequent infection by a pathogen such as a viral, bacterial, parasitic or other infectious agent. Preferably the target antigen is a

5 pathogen or an antigen associated with an infectious disease, an allergen or a cancer. Examples of infectious disease include but are not limited to viral, bacterial, mycobacterial and parasitic disease. Examples of allergens include, but are not limited to, plant pollens, dust mite proteins, animal dander, saliva and fungal spores. Examples of tumour-associated antigens (TAAs) include, but are not limited to, live or irradiated tumor cells,

10 tumor cell extracts and protein subunits of tumour antigens. The antigen can also be a sperm protein for use in contraception. In some embodiments, the antigen is an environmental antigen. Examples of environmental antigens include, but are not limited to, respiratory syncytial virus ("RSV"), flu viruses and cold viruses. Pathogens which invade via the mucosa also include those that cause respiratory syncytial virus, flu, other upper

15 respiratory conditions, as well as agents which cause intestinal infections.

Amongst several known examples of other diseases against which an enhanced CMI response is important are the following: infection and disease caused by viruses such as but not limited to HIV, herpes simplex, herpes zoster, hepatitis C, hepatitis B, influenza,

20 Epstein-Barr virus, measles, dengue, HTLV-1 and human papilloma virus (HPV) (for example HPV 16); diseases caused by bacteria such as but not limited to *Mycobacterium tuberculosis* and *Listeria* sp, *Chlamydia*, *Mycobacteria*, *Plasmodium Falciparum*, *Legioniella* and enteropathogenic, enterotoxigenic, enteroinvasive, enterohaemorrhagic and enteroaggregative *E.coli* and diseases caused by Pathogenic protozoans which include

25 but which are not limited to malaria, *Babesia*, *Schistosoma*, *Toxoplasma* and *Toxocara canis* or by the protozoan parasites *Toxoplasma* and *Trypanosoma*. Furthermore, the administration regime described herein is expected to be of value in immunising against forms of cancer where T cell responses plays a protective role. Examples of cancers of mammals which may be treated using method and compositions of the present invention

30 include but are not limited to melanoma, metastases, adenocarcinoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, colon cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, leukemias, uterine cancer, breast cancer, prostate cancer, ovarian

cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and the like. In one embodiment the cancer is one which is linked to (for example caused by HPV, e.g. HPV 16). Such a cancer may be a cervical cancer.

## 5 CANCER

In one preferred embodiment the use of an NOI encoding an EOI from a tumour associated target antigen (TAA) in the method of the present invention allows for the development of targeted antigen-specific vaccines for cancer therapy. The administration of an NOI encoding an EOI from a TAA and optionally an NOI encoding an immunomodulatory molecule provides a powerful system to elicit a specifically enhanced CMI response in terms of prevention in a host subject with an increased risk of cancer development (preventive immunisation), prevention of disease recurrence after primary surgery (anti-metastatic vaccination), or as a tool to expand the number of T cells *in vivo*, thus improving their effectiveness in eradication of diffuse tumours (treatment of established disease).

10 Furthermore, the method of the present invention may be used to elicit an enhanced CMI response in a host subject by the treatment of cells *ex vivo* prior to being transferred back to the tumour bearer (also known as adoptive immunotherapy). The method or process of the present invention can be used to administer the noi into the host subject either prior to any evidence of cancers such as melanoma (= preventative vaccination) or to mediate

15 regression of the disease in a mammal afflicted with a cancer such as melanoma (therapeutic or immunotherapeutic vaccination).

20

In one embodiment the NOI encodes an antigen from HPV (for example HPV 16), such as E6 or E7.

25

## ACTIVATED T-CELLS

In other aspects, the present invention involves a method of preparing activated T- cells. In its most general sense, this method includes administering, preferably transdermally, a NOI encoding a preselected EOI of a target antigen capable of enhancing a CMI response in terms of an enhanced T-cell response, to a host subject. In accordance with this aspect of the invention, the T-cells are recovered from lymph nodes of the host for further use.

30

Numerous potential uses of specifically activated T-cells are envisioned. For example, in the case of human therapy, it is contemplated that specifically activated T-cells may be cultured *ex vivo* and administered to humans for the treatment of viral infections or patients with cancer. In accordance with this aspect of the invention, the T-cells are prepared by 5 administering the NOI *in vivo* and then isolating the T-cells to expand *in vitro* in the presence of appropriate biological response modifiers and/or immunomodulators and/or adjuvants such as but not limited to peptide, cytokines and presenting cells.

#### HOMOLOGUES

10 Proteins (including protein antigens), such as Gag, nef and/or RT, as used in the invention (as encoded by the NOI) may have homology and/or sequence identity with naturally occurring forms. Similarly NOI coding sequences capable of expressing such proteins will generally have homology and/or sequence identity with naturally occurring sequences. Techniques for determining nucleic acid and amino acid "sequence identity" also are 15 known in the art. Typically, such techniques include determining the nucleotide sequence of the mRNA for a gene and/or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence.

20 In general, "identity" refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or more sequences (polynucleotide or amino acid) can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100.

25 An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2: 482-489 (1981). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff, *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 30 suppl. 3: 353-358, National Biomedical Research Foundation, Washington, D. C., USA, and normalized by Gribskov, *Nucl. Acids Res.* 14 (6): 6745-6763 (1986). An exemplary implementation of this algorithm to determine percent identity of a sequence is provided by

the Genetics Computer Group (Madison, WI) in the "BestFit" utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, WI). A preferred method of establishing percent identity in the context of the 5 present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S.

Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are 10 used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used 15 using the following default parameters: genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62 ; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs can be found at the following internet address: <http://www.ncbi.nlm.gov/cgi-bin/BLAST>.

20 Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease (s), and size determination of the digested fragments. Two DNA, or two polypeptide sequences are "substantially homologous" to each other 25 when the sequences exhibit at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules, as determined using the methods above.

As used herein, substantially homologous or homologous also refers to sequences showing 30 complete identity to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous or homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system.

For example, stringent hybridization conditions can include 50% formamide, 5x Denhardt's Solution, 5x SSC, 0.1% SDS and 100 pg/ml denatured salmon sperm DNA and the washing conditions can include 2x SSC, 0.1% SDS at 37 C followed by 1x SSC, 0.1% SDS at 68 C. Defining appropriate hybridization conditions is within the skill of the art.

5

#### TRADITIONAL IMMUNISATION PROTOCOLS

In recent years, improved immune response in terms of a humoral response (ie an antibody response) have been obtained by varying the immunisation regime for delivering the protein antigen. There is evidence that in some instances, antibody responses are improved 10 by using a clustered immunisation regime. In this regard, a study by Kilpatrick *et al* (1997) (In Hybridoma (1997) 16: 381-389) discloses a shortened repetitive immunisation regime using multiple site (RIMMS) introduction of antigen that employs a dual adjuvant strategy to produce a humoral response to a target protein antigen. The immunisation regime included:

15

Five RIMMS immunisations of protein antigen emulsified in Freund's Complete Adjuvant (FCA) and RIBI's adjuvant which were injected into twelve subcutaneous sites on days 0, 3, 6, 8 and 10 (with intervals of 72H or 48H between administrations) in order to generate affinity matured monoclonal antibody. Minor modifications to the RIMMS methodology 20 was apparently made (but not disclosed) to allow for DNA immunisation with ACCELL™ gene gun and biolistic particle bombardment.

The sole purpose of study disclosed in Kilpatrick *et al* (1997) was to reduce the time necessary for generating affinity matured monoclonal antibodies (Mabs) and not to assess 25 the possible protective efficacy of the produced antibodies in the animal model used. Moreover, the effect of the immunisation regime on the CMI response and in particular the effect of the immunisation regime on T cell production/activation was not measured in this study. In addition, there was no disclosure or suggestion that the immunisation schedule used could be used to enhance T cell production either with a protein antigen or with an 30 NOI encoding the target antigen or an EOI associated with the target antigen. What is more, there was no disclosure or suggestion of the use of such an immunisation regime to identify candidate agents capable of enhancing or modulating the CMI response.

A follow up paper by Kilpatrick *et al* (1998) (in *Hybridoma* (1998) 17: 569-576) relates to DNA immunisation with ACCELL™ gene gun and biolistic particle bombardment to reduced the time necessary to generate affinity matured Mabs. The disclosure in Kilpatrick 5 *et al*(1998) teaches that a DNA immunisation regime was used which included five RIMMS immunisations of DNA coated gold particles encoding Glt-3/hu Fc over the course of 11 days using the ACCELL™ gene gun. Two shots of DNA/gold encoding the Flt-3/hu Fc was delivered to two sites of the epidermis (see Fig 1) on the underside of mice on Days 0, 4, 6, 8 and 11 (ie with intervals of 96H, 24H and 48H between administrations) using the 10 Helium driven ACCELL™ gene gun. Bullets containing DNA encoding murine GM-CSF was delivered 3 days prior to the Flt-3/Fc DNA immunisations (see materials and methods).

Once again, the sole purpose of the study disclosed in Kilpatrick *et al* (1998) was to reduce the time necessary for generating affinity matured monoclonal antibodies (Mabs) and not to 15 assess the possible protective efficacy of the produced antibodies in the animal model used. Moreover, the effect of the DNA immunisation regime on the CMI response and in particular the effect of the immunisation regime on T cell production/activation was not measured in this study. In addition, there was no disclosure or suggestion that the DNA 20 immunisation schedule used could be used to enhance T cell production with an NOI encoding the target antigen or an EOI associated with the target antigen. What is more, there was no disclosure or suggestion of the use of such an immunisation regime to identify candidate agents capable of enhancing or modulating the CMI response.

The Kilpatrick *et al* (1998) study concludes that, when compared to conventional 25 methodologies or intramuscular targeted DNA-based immunisation for the generation of Mabs, the use of gene gun in conjunction with RIMMS allows for a more rapid production of affinity-matured Mab-producing cell lines (see Abstract). However, Kilpatrick *et al* (1998) also states that:

30 “*immunisation of the epidermis in mice using biolistic bombardment with DNA-coated gold particles has been found to bias Th2 responses which promotes the production of IgG1*

*subclasses. This is in contrast to intradermal or intramuscular DNA-based immunisation which bias Th1 responses”*

Kilpatrick *et al* (1998) also states that:

5    *“rapid translocation of the LC (Langerhans cells) following particle bombardment also diminishes the chance for a localised adjuvant effect that would mediate Th1 reactions”*

Thus, Kilpatrick *et al* (1998) points away from the present invention which actually demonstrates that NOI administration into the epidermis will actually enhance a CMI  
10 response and/or a T cell, such as a CD8+ T cell response which is a Th1 based response.

Reference is also made in Kilpatrick *et al* (1997) to studies carried out by Pertmer *et al* (1995) (in Vaccine (1995) 13; 1427-1430) and Olsen *et al* (1997) (in Vaccine (1997) 15; 1149-1156). Pertmer *et al* (1995) provide comparative data obtained from DNA  
15 immunisation of mice using gene gun based DNA immunisation and intra-muscular inoculation. Six groups of mice were each immunised on days 0 and 28 with plasmid DNA encoding the relevant antigen either by intradermal inoculation or via particle-mediated DNA delivery (gene gun) to the abdominal epidermis. The authors of the study conclude that particle-mediated DNA immunisation is an effective means of eliciting humoral and  
20 CTL responses in animal models when there is a time interval of at least 28 days between plasmid DNA administration. Pertmer *et al* do not disclose or suggest that a time interval between plasmid DNA administration of less than 28 days would be an effective means of eliciting either a humoral or a cytotoxic T cell response.

25    The Olsen *et al* (1997) study relates to DNA vaccination of mice *in vivo* by ACCELL™ gene gun delivery of plasmid DNA encoding the Eq/KYHA gene. When two doses of DNA vaccine were administered 3 weeks apart (ie with a time interval between DNA administrations of 21 days), mice were not protected from viral challenge although they cleared the infection, when challenged, more rapidly than control mice. However, when  
30 the second DNA vaccination was delayed until 9 weeks after the first (ie 63 time interval between DNA administrations), 9 out of 10 vaccinated mice were completely protected. The authors of this study conclude that the time between the initial and booster DNA

vaccinations may be an important variable in determining DNA vaccination efficacy. Thus the authors of the study seems to be pointing towards a time interval between DNA administrations of at least 63 days in order to obtain a completely protective effect from viral challenge. Moreover, the authors of this study only measure virus specific ELISA 5 antibodies or virus neutralising antibody production. There is no reference to the effect of the DNA immunisation regime on either the CMI response or a T cell response.

In summary, the Pertmer *et al* (1995) and Olsen *et al* (1997) studies cited in Kilpatrick *et al* 10 (1997) teach that some level of partial or complete protection against an NOI encoding a target antigen can be obtained when a conventional prime/boost vaccination regime using a time interval of either three weeks (21 days), nine weeks (63 days) (Olsen *et al* (1997)) or a conventional time interval of 28 days (Pertmer *et al* (1995)) between prime and boost vaccination doses were used. In no instance was an effective means disclosed or demonstrated for inducing an enhanced early or accelerated CMI response to protect 15 against a subsequently encountered target antigen and/or to treat (eg immunomodulate) and existing disease associated with the target antigen.

As discussed above, Pertmer *et al* (1995) (*ibid*) have demonstrated that a relatively long time interval (ie in terms of weeks) between prime and boost vaccinations will work in the 20 sense of enhancing a CMI response in terms of CTL production. In addition, Prayaga *et al* ((1997) (*ibid*) have shown that, in general, when a longer time interval between immunisations is used, a better CTL response is obtained. Whilst there is no evidence that a time interval between prime and boost immunisations of less than 28 days would not be effective in terms of inducing an enhanced CMI response, the received wisdom in the field 25 has been that a relatively long time interval (typically in terms of weeks rather than days) is required to elicit an effective CMI response. Even though a relatively short time interval between prime and boost immunisations could have been explored by workers in the field, there would have been no incentive for them to do so. Given that workers in the field have shown that too short a time interval between immunisations is detrimental to antibody 30 production, this would have dissuaded others from using a shorter time intervals between immunisations to boost a CMI response and would point away from the clustered NOI administration schedules of the present invention.

## ASSAY METHODS FOR IDENTIFYING CANDIDATE AGENTS

The present invention also provides a method of identifying a candidate agent capable of enhancing or modulating a CMI response. As used herein, the term "candidate agent" refers to any agent to which a cell mediated immune (CMI) response may be directed, and includes target antigens, pathogens and candidate EOIs. The identified candidate agent may be an epitope or any kind of adjuvant or biological response modifier or immunomodulator capable of enhancing and/or modulating CMI response.

10

Typically, the candidate agent to be tested for CMI enhancing capability will comprise one or more NOIs believed to have or suspected of having useful T-cell enhancing activities. Through the application of the method or process of the present invention to such NOIs, it is possible to determine whether such NOIs do in fact have CMI enhancing capability in terms of, for example, T-cell activating activity. If so, then the NOI may be suitable for inclusion in prophylactic or therapeutic vaccine for enhancing the CMI response.

To identify candidate agents capable of enhancing or modulating a CMI response, an NOI encoding the agent and optionally an adjuvant capable of enhancing a CMI response is administered to a host subject using the method or process of the present invention. The T-cells are recovered from the host subject and their activity, including systemic distribution and longevity may be determined. A candidate agent capable of enhancing a T-cell response may be identified as an agent that increases the CMI response, using any of the parameters as already discussed over that observed from a reference substance. A candidate agent capable of modulating a CMI response may be identified as an agent which is capable of preventing, suppressing, alleviating, restoring, down-regulating or modifying a CMI response relative to that observed from a reference substance.

The assay/screening methods of the present invention generally include the steps of (i) administering a NOI encoding the candidate agent to a host subject such as a human subject or an experimental animal such as a mouse, rat, rabbit, guinea pig, goat, rhesus monkey, or chimpanzee; (ii) thereafter collecting cells from spleen or other lymphoid tissue from the

host subject, and (iii) testing the tissue for the presence of activated T-cells, such as T cells that are primed to kill or lyse cells producing a component of an infectious agent.

Once NOI administration has been effected, the T-cells from the lymphoid tissue of the host subject are recovered. The preferred lymphoid tissue will be lymph node tissue, and 5 most preferably tissue from draining lymph nodes proximal to the site of NOI administration. As used herein, the word "proximal node" is intended to refer to the node or nodes that are located proximal to the site of NOI administration.

Such nodes are physically located in the proximity of the site of NOI administration or in 10 the area draining the site of administration, and also included are those draining nodes that are physically at a greater distance from the administration site.

The final step of the assay method involves determining whether the T-cells have been activated by the candidate composition. Typically, the level of T-cell activation can be 15 measured by assays which include but are not limited to radioactive chromium-release assays, or other radioisotope assays, or single cell assays. In addition, single cell T-cell assays using vital stains and/or cell sorters may be employed. A preferred method for measurement of activation of T-cells involves contacting a killing effective amount of the T-cells with MHC-matched target cells that exhibit the candidate EOI on their cell surfaces; 20 maintaining the contact for a time period sufficient for the T-cells to lyse the target cells; and determining the degree of T-cell mediated lysis of the target cells. However, any method capable of detecting a specific T-cell response may be employed, including but not limited to chromium release assays, single-cell assays or even determination of cell-cell conjugates.

25

#### IDENTIFIED AGENT

Once an agent capable of enhancing/activating or modulating the T-cell response has been identified, further steps may be carried out either to select and/or to modify the agent to improve the T-cell activating, enhancing or modulating capability.

30

#### APPLICATION OF THE IDENTIFIED CANDIDATE AGENTS

The assay method of the present invention has a broad range of application, particularly in the identification of candidate agents for use in medicine such as, for example in the preparation of prophylactic and/or therapeutic vaccines for the treatment and/or prevention of viral diseases such as AIDS, influenza, feline leukemia, bovine leukemia, Herpes virus infections, and non-viral infectious diseases such as parasitic and bacterial infections. Therefore, in the case of, for example, embodiments directed to the identification of EOIs for enhancing a specific anti HSV CMI response, the invention will generally be concerned with the identification of agents having the ability to direct a T-cell response to HSV-infected cells.

10

In the context of vaccine development, the method will include first identifying an agent in accordance with the foregoing method, and admixing the agent with one or more pharmaceutically acceptable diluents or additives, such as water, salts, emulsifiers and/or adjuvants. Of course, the amount of the agent added to a particular composition will vary depending on its ability to elicit an enhanced CMI response, its solubility, and other biological responses. The selection of an appropriate amount of the identified candidate agent will therefore be well within the skill of the art in light of the present disclosure.

20

In one preferred embodiment, the assay method of the present invention is used to identify candidate agents capable of selectively enhancing a CMI response but which do not elicit an enhanced antibody immune response. Thus, the candidate agents may be screened to identify those that lack B cell stimulatory activity. Such identified agents may be particularly useful in the preparation of vaccines for the treatment or prevention of T cell mediated disorders where an antibody response may in fact enhance infectivity of the causative agent.

25

In another preferred embodiment, the assay method of the present invention is used to identify candidate agents capable of selectively modulating a CMI response in terms of preventing or suppressing or down regulating an enhanced CMI response. Such an identified agent may be used in the prevention and/or treatment of autoimmune disorders which include but which include but are not limited to diabetes (such as insulin dependent

**diabetes mellitus (IDDM), arthritis, multiple sclerosis, irritable bowel disease (IBD), graft versus host disease (GVHD) (see for example, the teachings in WO 97/02045).**

## COMPOSITIONS

The present invention provides compositions that are useful for preventing and/or treating T cell mediated immune disorders. In one embodiment, the composition is a pharmaceutical composition. In another preferred embodiment, the composition is an immunotherapeutic composition. In an even more preferred embodiment, the composition is a vaccine composition. The composition can comprise a therapeutically or prophylactically effective amount of an NOI encoding an EOI of a TA of the invention as described above. The composition may also comprise a carrier such as a pharmaceutically or immunologically acceptable carrier. Pharmaceutically acceptable carriers or immunologically acceptable carriers are determined in part by the particular composition being administered as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions or vaccine compositions or immunotherapeutic compositions of the present invention.

## 15 FORMULATIONS

The NOI may be formulated into a pharmaceutical composition or an immunotherapeutic composition or a vaccine composition. Such formulations comprise the NOI combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers containing a preservative. Formulations include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (for eg, a powder or granules) form for reconstitution with a suitable vehicle (e. g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition. The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or

suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono-  
5 or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble  
10 polymer, or a sparingly soluble salt. Kits Also included in the invention is a kit for enhancing a CMI response to an EOI of a target antigen. Such a kit comprises an NOI encoding an EOI of a TA. The kit may also include an adjuvant, preferably a genetic adjuvant is administered with or as part of the NOI and instructions for administering the NOI. Other preferred components of the kit include an applicator for administering the  
15 NOI. As used herein, the term "applicator" refers to any device including but not limited to a hypodermic syringe, gene gun, particle acceleration device, nebulizer, dropper, bronchoscope, suppository, impregnated or coated vaginally-insertable material such as a tampon, douche preparation, solution for vaginal irrigation, retention enema preparation, suppository, or solution for rectal or colonic irrigation for applying the NOI either  
20 systemically or mucosally or transdermally to the host subject.

## EXAMPLES

The following invention will now be further described only by way of example in which reference is made to the following Figures. The following examples are presented only to  
25 illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

30

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides (CD8+ T cell) responses after 1, 2 or 4 NOI administrations to mice during 1 week at day 7 (D 7), days 0 and 7 (D 0,7) or days 0, 2, 4, and 7 (D 0,2,4,7) respectively. Either 1 or 2 shots per NOI administration were given, and in one group LT adjuvant was co-administered with the NOI.

5

Figure 1A demonstrates the CD8+ T cell response after administration of the ICP27 single gene plasmid.

Figure 1B demonstrates the CD8+ T cell response after administration of the PJV7630 10 multi- gene plasmid.

Figure 2 demonstrates protection of mice from infectious challenge using clustered NOI administration.

15 Figure 3A demonstrates optimal time intervals between clustered administrations Of the ICP27 single gene plasmid.

Figure 3B demonstrates antibody responses obtained after clustered NOI administration of HbsAg single gene plasmid.

20

Figure 3C demonstrates antibody titre obtained after clustered NOI administration of HbsAg single gene plasmid.

25 Figure 4A demonstrates ELISPOT measurements 1 week post administration of clustered NOI administrations of a multigene plasmid (PJV7630) at intervals of 0, 1, 2, 4 and 6 days between administrations

Figure 4B demonstrates ELISPOT measurements 3 weeks post administration of clustered 30 NOI administrations of a multigene plasmid (PJV7630) at intervals of 0, 1, 2, 4 and 6 days between administrations.

Figure 5A is a schematic diagram showing that each “administration” is made up of 1 to 4 XRI administrations and the resting period between each administration.

Figure 5B shows the CMI response in terms of IFN-gamma release obtained from a combination of genetic LT adjuvant and a clustered NOI administration schedule.

5 Figure 5C shows the antibody response obtained from a combination of genetic LT adjuvant and a clustered NOI administration schedule.

Figure 6A shows IFN- $\gamma$  ELISPOT data obtained from animals following the first cluster immunization.

10 Figure 6B shows the average area of erythema present at the site of antigen administration in pigs (4 animals) immunized with pPJ7630.

Figure 7 shows an anti-HA antibody response in domestic pigs.

15 Figure 8 shows plasmid pPJ1671 which is a human DNA vaccine vector encoding the hemagglutinin (HA) antigen of influenza A/Panama/2007/99 (H3N2).

Figure 9 shows a comparison of H3 Panama HA Natural Sequence with a H3 Panama HA  
20 Encoded by pPJ1671 and a Consensus sequence.

Figure 10 shows a plasmid map of pPJ2012.

Figure 11 shows a plasmid map for pPJ7563.

25 Figure 12 provides a nucleotide sequence for the pPJ7563 plasmid.

Figure 13 provides a flowchart outlining the construction of PJV7563.

Figure 14 (i) to (viii) provides the Feature Maps of Key Plasmids in the Construction of  
30 pPJ7563.

Figure 15 provides a Flowchart Derivation of Plasmids WRG7074 and WRG7128.

Figure 16 (i) to (v) provides Further Key Plasmid Feature Maps

Figures 17 to 22 relate to constructs that express HIV antigens and to sequences that  
5 encode HIV antigens.

Figures 23 to 28 relate to immunization with HPV E6 and E7 antigens.

## GENERAL TECHNIQUES

Unless otherwise indicated, the recombinant DNA techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A

5 Practical Guide to Molecular Cloning, John Wiley and Sons (1984); J. Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989); T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991); D. M. Glover and B. D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996); and F. M. Ausubel *et al.* (editors),  
10 Current Protocols in Molecular Biology, GreenePub. Associates and Wiley-Interscience (1988, including all updates until present) and are incorporated herein by reference. The method or process of the present invention involves the direct *in vivo* introduction of an NOI encoding at least one or more EOI of a TA into tissues of a subject for expression of the EOI by the cells of the subject's tissue.

15

Methods of making constructs useful in the methods of this invention. The NOI constructs of the present invention may be prepared by conventional methods known to one of skill in the art. Methods for constructing of the DNA plasmid or recombinant vectors are described in conventional texts, such as Burger *et al.*, *J. Gen. Virol.*, 72: 359-367 (1991), and are well-known in the art. See also Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York; and Ausubel *et al.*, 1997, Current Protocols in Molecular Biology, Green & Wiley, New York.

25 By way of example, NOIs which encode one or more EOIs of the TA or sequences sufficiently homologous to known EOIs of TA to induce CMI responses may be obtained by following well known procedures described in the art for the isolation of NOIs from a variety of microorganism sources. Alternatively, the NOIs encoding the EOIs of the TA may be synthesized in a nucleic acid synthesizer. Thus, the invention includes synthetic forms of NOIs encoding EOIs of the TA. Other recombinant bacterial plasmids or viral  
30 vectors which contain such isolated NOIs and which are preferably capable of directing expression of the EOI of the TA encoded by the NOI in a host cell; and cells containing such vectors, either eukaryotic or prokaryotic cells, preferably eukaryotic cells are also

prepared by known techniques. To ensure expression of the EOI of the TA by the NOI in plasmid or viral vector form, the NOI is operably linked to a promoter/regulatory region capable of driving high levels of expression of the antigen in the host cells. Many such promoter/regulatory sequences are available in the art including, but not limited to, for 5 example, the human cytomegalovirus immediate early promoter/enhancer sequence, the SV40 early promoter, the Rous sarcoma virus promoter and other mammalian promoter/enhancer sequences. As used herein, the term "promoter/regulatory sequence" refers to a DNA sequence which is required for expression of an NOI operably linked to the promoter/regulatory sequence. In some instances, the promoter/regulatory sequence may 10 function in a tissue specific manner, in that, the promoter/regulatory sequence is only capable of driving expression in a cell of a particular tissue type. Unless otherwise indicated, selection of any particular plasmid vector or otherDNA vector or viral vector is not a limiting factor in this invention and other DNA or viral vectors may be substituted for those disclosed herein upon a reading of the present disclosure. It is well within the skill of 15 the artisan to choose particular promoter/regulatory sequences and operably link those promoter/regulatory sequences to a DNA sequence encoding a desired antigen. Such technology is well known in the art and is described, for example, in Sambrook (*ibid*), and Ausubel (*ibid*).

20 The following general methods were used to carry out the studies described in Examples 1- 5 below. In each study, NOIs comprising EOIs were coated onto gold particles in order to provide exemplary compositions according the present invention. The coated particles were administered to animal subjects, and the ability of the compositions to elicit antigen specific T cell and/or antibody responses was assessed.

25

#### CORE CARRIER PARTICLE COATING

Appropriate weights of gold particles were weighed directly into 1.5 mL Eppendorf tubes. Approximately 300  $\mu$ L of a 0.05M spermidine solution was then added to suspend the gold, using a sonicator to disperse the gold. A solution (approximately 50  $\mu$ L) containing the 30 relevant DNA plasmid was then added to the gold/spermidine solution at a concentration of 2  $\mu$ g DNA/mg gold. The DNA solution may contain one type of plasmid, or for certain experiments two or more plasmids (a genetic adjuvant for example) can be mixed together

prior to the mixing with the gold solution. The DNA/gold mixture was vortexed at a gentle speed and 300  $\mu$ L of a 10% CaCl<sub>2</sub> solution was added dropwise while vortexing. The DNA/gold particles were allowed to precipitate at room temperature and then centrifuged briefly (10-15 seconds) to pellet the gold. The pellet was washed three times with 5 approximately 800  $\mu$ L of EtOH. The DNA/gold particles were then suspended in a 0.03 mg/mL PVP (polyvinylpyrrolidone) solution made up in EtOH at approximately 1 mg DNA/gold in 3 mL of PVP solution. This solution was then coated onto Tefzel tubing as previously described. See e.g., PCT patent application PCT/US95/00780 and US patent Nos. 5,733,600; 5,780,100; 5,865,796 and 5,584,807 the disclosures of which are hereby 10 incorporated by reference.

#### HEPATITIS B SURFACE ANTIGEN (HBsAG)

#### CONSTRUCTION OF PLASMID (PWRG7128 CONSTRUCT)

A Hepatitis B surface antigen (HBsAg) vector plasmid was constructed as follows. To 15 generate the HbsAg coding region, the pAM6 construct (obtained from the American Type Culture Collection "ATCC") was cut with *Nco*I and treated with mung bean nuclease to remove the start codon of the X-antigen. The resultant DNA was then cut with *Bam*HI and treated with T4 DNA polymerase to blunt-end the DNA and create an HBsAg expression cassette. The HBsAg expression cassette is present in the 1.2 kB fragment. The plasmid 20 construct pPJ7077 (Schmaljohn et al. (1997) *J. Virol.* 71:9563-9569) which contains the full-length human CMV (Towne strain) immediate early promoter (with enhancer) was cut with *Hind*III and *Bgl*II, and then treated with T4 DNA polymerase and calf-alkaline phosphatase to create blunt-ended DNA, and the HBsAg expression cassette was ligated into the plasmid to yield the pWRG7128 construct.

25

#### IN VITRO IMMUNE ASSAYS

Serum samples of individual mice were tested for antibodies specific for HBsAg using an 30 ELISA assay. For the ELISA, Falcon Pro Bind microtiter plates were coated overnight at 4°C with purified HBsAg (BioDesign) at 0.1  $\mu$ g per well in PBS (phosphate buffered saline, BioWhittaker). The plates were blocked for 1 hour at room temperature (RT) with 5% dry milk/PBS then washed 3 times with wash buffer (10 mM Tris Buffered saline, 0.1% Brij-35), and serum samples diluted in dilution buffer (2% dry milk/PBS/0.05 % Tween 20)

were added to the plate and incubated for 2 hours at RT. The plates were washed 3 times and a biotinylated goat anti-mouse antibody (Southern Biotechnology) diluted 1:8000 in dilution buffer was added to the plate and incubated for 1 hr at RT. Following the incubation, plates were washed 3 times, after which a Streptavidin-Horseradish peroxidase 5 conjugate (Southern Biotechnology) diluted 1:8000 in PBS was added and the plate incubated a further 1 hr at RT. After an additional three washes, Plates were washed 3 times, then a TMB substrate solution (BioRad) was added and the reaction was stopped with 1N H<sub>2</sub>SO<sub>4</sub> after 30 minutes. Optical density was read at 450 nm. Endpoint titers were calculated by comparison of the samples with a standard of known titer.

10

For the cellular immune assays, single cell suspensions of splenocytes from the spleens of the immunized animals were cultured *in vitro* in the presence of a peptide corresponding to a known CD8 epitope in Balb/c mice. The peptide was dissolved in DMSO (10 mg/ml) and diluted to 10 ug/ml in culture. The sequence of the peptide was IPQSLDSWWTS (SEQ 15 ID NO: 20).

For IFN- $\gamma$  ELISPOT assays, Millipore Multiscreen membrane filtration plates were coated with 50  $\mu$ l of 15  $\mu$ g/ml anti-IFN- $\gamma$  antiserum (Pharmingen) in sterile 0.1 M carbonate buffer (pH 9.6) overnight at 4°C. Plates were washed 6 times with sterile PBS and then blocked 20 with tissue culture medium containing 10% fetal bovine serum (FBS) for 1-2 hr at RT. The medium was removed and spleen cells dispensed into the wells with a total of 1x10<sup>6</sup> cells per well. For wells in which less than 1x10<sup>6</sup> cells from immunized animals was added, cells from naïve animals were used to bring the total to 1x10<sup>6</sup>. Cells were incubated overnight in a tissue culture incubator in the presence of the peptide as described above. 25 The plates were then washed 2 time with PBS and 1 time with distilled water. This was followed by 3 washes with PBS. A biotinylated anti IFN- $\gamma$  monoclonal antibody (Pharmingen) was added to the plate (50  $\mu$ l of a 1  $\mu$ g/ml solution in PBS) and incubated for 2 hr at RT. The plates were washed 6 times with PBS after which 50  $\mu$ l of a Streptavidin Alkaline phosphatase conjugate (1:1000 in PBS, Pharmingen) was added and incubated for 30 2 hr at RT. The plates were washed 6 times with PBS and an alkaline phosphatase color substrate (BioRad) was added and the reaction was allowed to proceed until dark spots

appeared. The reaction was stopped by washing with water 3 times. Plates were air dried and spots counted under a microscope.

#### HIV-1 GP120 ANTIGEN

##### 5 CONSTRUCTION OF PLASMID ENCODING HIV-1 GP120 ANTIGEN

A plasmid vector encoding HIV-1 gp120 was constructed as follows. The vector was constructed starting with a Bluescript (Stratagene, La Jolla, CA) plasmid backbone, the human cytomegalovirus (hCMV) immediate early promoter (Fuller et al. (1994) *Aids Res. Hum Retroviruses* 10:1433) and the SV40 virus late polyadenylation site. The hCMV promoter is contained within a 619 base pair (bp) *Acc*II fragment extending 522 bp upstream and 96 bp downstream from the immediate early transcription initiation site. The SV40 virus late polyadenylation sequence is contained within an approximately 800 bp *Bam*HI-*Bgl*II fragment derived from pSV2dhfr (formerly available from Bethesda Research Laboratories, catalogue #5369 SS). Initially, a plasmid encoding HIV-1 gp160, termed "pC-Env" was constructed. This plasmid contains a 2565 bp *Kpn*I-*Xho*I fragment from LAV-1<sub>BRU</sub> (ATCC Accession No. 53069, GenBank Accession No. K02013), which begins at the sequence encoding amino acid position #4 of the mature gp160 amino terminus. The *env* coding sequence fragment was placed immediately downstream of, and fused in frame with a 160 bp synthetic fragment encoding the herpes simplex virus glycoprotein D (gD) signal peptide and none amino acids of the mature gD amino terminus as previously described (Fuller et al. (1994) *Aids Res. Hum Retroviruses* 10:1433).

The plasmid encoding HIV-1 gp120, termed "pCIA-Env/T" herein, was then constructed as follows. The pCIA-Env/T plasmid encodes a truncated form of HIV-1 gp160, and is identical to the pC-Env construct except that the *env* coding sequences are truncated at the *Hind*III site at nucleotide position 8188. This results in a truncated gp160 translation product with the truncation point lying 128 amino acid residues downstream of the gp120/gp41 processing site.

##### 30 IN VIVO IMMUNE ASSAYS

Serum antibody responses to the HIV gp120 antigen were tested using an ELISA assay on specimens collected at week 5 and week 6.5 (post-prime and post-boost, respectively). For

the ELISA, Costar high binding EIA plates were coated with 0.3  $\mu$ g/well of recombinant HIV gp120 (Intracel) in 50  $\mu$ l PBS by incubation overnight at 4°C. Plates were washed three times and blocked with 2% BSA in PBS for 2 hours at room temperature. Serial dilutions of serum were added to the coated plates, and incubated at 37°C for one hour.

5 After washing, the plates were incubated with a 1:1500 dilution of alkaline phosphatase conjugated goat anti-mouse IgG (H+L) (BioRad), followed by color development with p-nitrophenylphosphate (PNPP) (BioRad) and OD reading @ 405nm.

10 The amount of antigen-specific IFN- $\gamma$  secreted by the splenocytes was determined using a cytometric bead assay. 1  $\times$ 10<sup>6</sup> splenocytes were added to each well of a 96 well plate and were stimulated in medium alone (negative control), or in medium with 1  $\mu$ g/ml of a HIV gp120 peptide having the following sequence: RIQRGPGRGAFVITGK (SEQ ID NO: 21). Following a 48 hour incubation at 37°C in 5% CO<sub>2</sub>, supernatants were removed and IFN-gamma levels were measured by a cytometric bead assay (BD Biosciences).

15

#### HSV-2 ANTIGENS

#### CONSTRUCTION OF PLASMID ENCODING HSV-2 ICP27

A DNA vaccine encoding ICP27 was constructed and then combined with various combinations of the present adjuvant plasmid vectors to provide vaccine compositions.

20 After immunization, the immunized animals were challenged with HSV-2 virus, and the protective effect of the various vaccine compositions was determined.

25 With respect to the construction of the DNA antigen plasmid, standard PCR techniques were used to construct the plasmid. The standard PCR conditions that were used for the construction of the vector were as follows: 1x PCR core buffer with 1.5 mM MgCl<sub>2</sub> (Promega Corp., Madison, WI); 0.400  $\mu$ M of each primer; 200  $\mu$ M of each dNTP (USB Inc., Cleveland, OH); 2.5  $\mu$ g Taq polymerase (Promega Corp., Madison, WI); 1.0 ng template DNA; water to 100  $\mu$ l; and a mineral oil (Aldrich Chemical Inc., Milwaukee WI) overlay. A PTC-200 thermocycler (MJ Research Inc., Waltham, MA) was programmed to

30 run the following routine: 4 minutes @ 95°C; 30 cycles of (1 minute @ 95C/ 1 minute 15 seconds @ 55C/ 1 minute @ 72°C); 10 minutes @ 72°C; 4°C hold. The amplification products were removed from the PCR reaction using the QIAquick7 PCR Purification Kit

(Qiagen Inc., Valencia CA) prior to cutting with restriction enzymes (New England Biolabs, Beverly, MA).

More specifically, a DNA vaccine plasmid vector encoding the HSV-2 early ICP27 antigen  
5 was constructed as follows. HSV is a double-stranded DNA virus having a genome of  
about 150-160 kbp. The viral genome is packaged within an icosahedral nucleocapsid  
which is enveloped in a membrane. The membrane (or envelope) includes at least 10 virus-  
encoded glycoproteins, the most abundant of which are gB, gC, gD, and gE. The viral  
genome also encodes over 70 other proteins, including a group of approximately five  
10 immediate early antigens. These early proteins are synthesized early in the viral replication  
cycle, in contrast to the envelope glycoproteins which are only made late in the life cycle of  
the virus. For a review of the molecular structure and organization of HSV, see, for  
example, Roizman and Sears (1996) "Herpes simplex viruses and their replication" in  
Fields Virology, 3rd ed., Fields et al. eds., Lippincott-Raven Publishers, Philadelphia, PA.  
15 The HSV-2 ICP27 antigen can be readily obtained from the HSV-2 genome, for example  
the genomic region spanning from approximately nucleotide 114589 to 134980 of the  
HSV-2 genome, or an *Eco*RI fragment that spans nucleotides 110931 to 139697 of the  
HSV-2 genome. The sequence of the HSV-2 genome is available from published sources,  
for example the sequence deposited with GenBank under Accession Number NC\_001798.  
20

In order to construct the ICP27 vector used in the present study, the ICP27 coding region  
was PCR'd from the HSV-2 genome using the following primers: 5'CGCC ACT CTC TTC  
CGA CACC3' (SEQ ID NO:25) and 5'CCAA GAA CAT CAC ACG GAA CC3' (SEQ ID  
NO:26) to obtain a nucleotide fragment containing nucleotide sequences 114523-116179  
25 (GenBank) of HSV-2 which correspond to the ICP27 coding region. The ICP27 fragment  
was then cloned into the multiple cloning region of the pTarget vector (Promega Corp.,  
Madison, WI).

**CONSTRUCTION OF THE PJV7630 PLASMID.**

The origins of the antigen genes for pPJ7630 are a genomic fragment of HSV-2 strain MS that had been cloned into a cosmid vector called cosmid 23. Cosmid 23 was composed of 3 EcoRI fragments from HSV-2 that spanned from nucleotides 110,931 to 147,530 based on 5 the published sequence (HG52 strain). Cosmid 23 was partially digested with EcoRI and re-ligated and a construct that had only the approximate 28,000 bp fragment (110,931 - 139,697) was selected. This molecule was designated OP23. From this molecule 6 modifications were made to alter sequences within the OP23. These were designed to remove non immediate early genes from the HSV-2 sequences and also backbone DNA 10 sequences. One final modification was to replace the backbone sequences with an appropriate antibiotic resistance gene for clinical use. The steps are described below.

1. Bst1107I and Scal digest and re-ligation (removes ampicillin resistance gene). Creates OP23-1.

15

2. NsiI digest and re-ligation to remove SV40 origin of replication. Creates OP23-2.

3. BstXI partial digest and re-ligation to remove regions between ICP27 and ICP0 to make OP23-3.

20

4. Complete digest with BspHI followed by partial with BsiWI then re-ligation to remove sequences following the ICP22 gene and some backbone sequences. Creates OP23-4.

25

5. SrfI digest and re-ligation to create OP23-5. Removes sequences between ICP4 and ICP0.

6. BstXI total digest and re-ligation to create OP23-6. Small fragment removed from between ICP27 and ICP0.

30

7. Replacement of backbone sequences coding for the antibiotic resistance gene, with a fragment containing a Kanamycin resistant gene to create pPJ7630.

The construct pJV7630 is large (19517 bases) and contains genes encoding the ICP0, ICP4, ICP22 and ICP27 immediate early antigens.

#### IN VITRO IMMUNE ASSAYS

##### 5 MICE

Single cell suspensions were obtained from mouse spleens. Spleens were squeezed through a mesh to produce a single cell suspension and cells were then sedimented, and treated with ACK buffer (Bio Whittaker, Walkersville MD) to lyse red blood cells. The cells were then washed twice in RPMI 1640 media supplemented with HEPES, 1 % glutamine (Bio 10 Whittaker), and 5% heat inactivated fetal calf serum (FCS, Harlan, Indianapolis IN). Cells were counted, and resuspended to an appropriate concentration in "Total" media consisting of RPMI 1640 with HEPES and 1% glutamine, supplemented with 5% heat inactivated FCS, 50  $\mu$ M mercaptoethanol (Gibco-BRL, Long Island NY), gentamycin (Gibco-BRL), 1 mM MEM sodium pyruvate (Gibco-BRL) and MEM non-essential amino acids (Sigma, St. 15 Louis MO). For the CD8 specific assays cells were cultured *in vitro* in the presence of a peptide corresponding to a known CD8 epitope. For ICP27 in BALB/C mice the sequence of the peptide was HGPSLYRTF (QCB Inc). Peptides were made up in DMSO (10 mg/ml) and diluted to 10  $\mu$ g/ml in culture medium.

20 For IFN- $\gamma$  ELISPOTs assays Millipore Multiscreen membrane filtration plates were coated with 50  $\mu$ L of 15  $\mu$ g/ml anti-IFN- $\gamma$  antiserum (Pharmingen) in sterile 0.1M carbonate buffer pH 9.6, overnight at 4 °C. Plates were washed 6X with sterile PBS and then blocked with tissue culture medium containing 10% fetal bovine serum (FBS) for 1-2 hr at RT. The medium was removed and spleen cells dispensed into the wells with a total of 1X10<sup>6</sup> cells 25 per well. For wells in which less than 1X10<sup>6</sup> cells from immunized animals was added, cells from naïve animals were used to bring the total to 1X10<sup>6</sup>. Cells were incubated overnight in a tissue culture incubator in the presence of the peptide as described above. Plates were washed 2X with PBS and 1X with distilled water. This was followed with 3 washes with PBS. Biotinylated anti IFN- $\gamma$  monoclonal antibody (Pharmingen) was added 30 to the plate (50 ul of a 1 ug/ml solution in PBS) and incubated for 2 hr at RT. Plates were washed 6X with PBS then 50  $\mu$ L of a Streptavidin Alkaline phosphatase conjugate (1:1000 in PBS, Pharmingen) was added and incubated for 2 hr at RT. Plates were washed 6X with

PBS and the color substrate (BioRad) was added and the reaction was allowed to proceed until dark spots appear. The reaction was stopped by washing with water 3X. Plates were air dried and spots counted under a microscope.

## 5 IN VIVO ASSAY

### MICE

An infectious challenge model was used to test the ability of different immunization schedules to protect mice from a lethal challenge with HSV-2. Mice were immunized prior to challenge and for infection were anesthetized and administered with a lethal dose of 10 HSV-2 intranasally in 30  $\mu$ L of PBS. Mice were followed for 20 days after infection and were scored for sickness and mortality.

## IN VITRO IMMUNE ASSAYS

### DOMESTIC PIGS

15 To isolate peripheral blood mononuclear cells (PBMCs) whole blood was spun through a Histopaque-1077 cushion (3000 rpm for 30 minutes) at room temperature and PBMCs recovered as a band from the gradient. PBMCs were washed 3X in total media and resuspended in 25 mLs of Total media for counting and were resuspended to  $1 \times 10^7$  cells/ml in Total media. The ELISPOT assay was carried out as described for mice with 20 the exception that the antigens were pools of peptides derived from overlapping peptide libraries of the HSV-2 antigens, and an anti-IFN antibody pair specific for domestic pig IFN- $\gamma$  (R&Dsystems) was used for detection.

## IN VIVO ASSAY

### DOMESTIC PIGS

Another assay used to examine immune responses in domestic pigs was a delayed type hypersensitivity (DTH) assay. This assay used both DNA plasmids and protein extracts as antigen sources that were delivered into the pig skin using the XR1 device and needle injections respectively. The area of redness (erythema) surrounding the delivery site of the 30 antigens was measured at 48 hrs after administration as an indicator of a DTH reaction. The antigen delivery into the skin was done 7 days after immunization was complete.

**EXAMPLE 1**

Two different plasmids comprising NOIs were used to immunize mice; These were: HSV-2 clinical vaccine multiple gene plasmid (PJV7630) and a single gene plasmid comprising the ICP27 NOI operably linked to the HCMV promoter. The ICP27 NOI encodes the 5 dominant epitope found in PJV7630 and the graphs represent CD8 responses specific for this protein.

**NOI Administration Schedule**

The NOI was administered 1, 2 or 4 times during 1 week either at day 7 (D 7), days 0 and 7 10 (D 0,7) or days 0, 2, 4, and 7 (D 0,2,4,7) respectively. Either 1 or 2 shots per NOI administration were given, and in one group LT adjuvant was co-administered with the NOI.

**Results**

15 The ICP27 gene is the dominant antigen found in PJV7630 and the Figures 1A and 1B represent CD8 responses specific for this target antigen.

Typically both plasmids PJV7630 (Fig 1B) and ICP27 (Fig 1A) generate 500 ELISPOTs/million cells after only one NOI administration and 1500 ELISPOTs/million 20 cells after two NOI administrations. When two NOI administrations are followed with the LT genetic adjuvant approximately 3500 ELISPOTs are found. Above 3500 ELISPOTs/million cells were obtained after four NOI administrations even in the absence of LT adjuvant but the LT genetic adjuvant will enhance the responses as well. In Fig 1A the response from the LT co-administered with the NOI was not measured as the results were off-scale.

25

**Summary**

Clustering NOI administrations had been found to generate enhanced cellular immune responses based on ICP27 specific CD8 IFN-gamma ELISPOTs measured in mice immunized with PJV7630.

**EXAMPLE 2**

The purpose of following three experiments was to assess whether an enhanced CMI response resulting from clustered NOI administrations of a single gene plasmid correlated with enhanced protection from lethal challenge.

5

**Methodology**

Plasmid PJV7630 was administered to mice over a one week period. Either one (day 7), two (days 0 and 7) or 4 (days 0, 2, 4 and 7) NOI administrations were given over the period of one week. One group received 2 doses at each immunization but the majority of mice 10 received a single dose of PJV7630 at each immunization.

**Results**

On the graphs the labeling is “number of administrations x number of doses per administration” so that 4 x 1 are animals given 4 NOI administrations with a single dose at 15 each administration. Following a week of NOI administration, the animals were rested either 1 week or 2 weeks before infected with virus. The dose of virus was approximately 5 times the LD50.

Figure 2A shows results from C57Bl/6 mice after 2 weeks rest. The results clearly 20 demonstrate that a 4x1 schedule (ie 4 administrations x 1 dose per administration) was more protective. This result does not appear to result from the increased dose since 2x2 (ie 2 NOI administrations x 2 doses) also has 4 doses in total.

Figure 2B shows results from C57Bl/6 mice after 1 week rest. It is clear from Figure 2B 25 that virtually the same results were obtained as for the two week rest shown in Figure 2A. However, in Figure 2B there is an additional group with just one NOI administration.

Figure 2C shows results from Balb/c mice after 1 week rest. It is clear from the results that the challenge dose was not high enough to get a clear difference in mortality, but there were 30 differences in sickness. The numbers in brackets are sickness scores with the higher the number the sicker the animals. The results are in line with those from Figures 2A and 2B which show that 4x1 (ie 4 administrations x one dose) confer the best protection.

**Summary**

The clustering of 4 administrations x one dose per administration in 1 week rapidly generates a strong protective CMI response that is stronger than single administrations or using more doses per administration.

5

**EXAMPLE 3**

The purpose of this experiment was to vary the time interval between DNA administrations of a single gene plasmid.

**10 Methodology**

All the mice were given a total of 4 administrations with differences between the date of receipt of each administration and time interval between administrations. Mice had 6, 4, 2, 1 or 0 day intervals between administrations (ie, 0 had 4 shots on one day). The final administration of each schedule was given on the same calendar day and then all animals

15 were sacrificed 7 days after the final administration.

**Results**

Figure 3A provides measured CD8 ELISPOTs results for 0, 1, 2, 4 and 6 day time intervals between clustered administrations of a ICP27 single gene plasmid. The results show that

20 increasing the time interval between administrations enhances the CD8 ELISPOT results with a maximum results obtained when there was a 4 day interval (ie 96hours) between NOI administrations.

**Summary**

25 Examination of time intervals between clustered NOI administrations in mice demonstrated that when 4 NOI administrations are given, optimal responses in terms of a CD8+ T cell response are obtained when the NOI administrations are spaced 4 or 6 days apart.

30 Figures 3B and 3C provide measured antibody results from clustered administration of the HbsAg single gene plasmid. The antibody titres obtained are quite weak. These results suggest that clustered NOI administrations with 0, 1, 2, 4, or 6 day intervals between

administrations does not seem to enhance antibody titer even though the CD8+ T cell response is enhanced.

#### EXAMPLE 4

5 The purpose of this experiment was to assess the CMI response in terms of CD8+ T cell response for clustered NOI administration of a multi gene plasmid (PJV7630).

##### Methodology

10 Animals were given 4 NOI administrations in total but the time interval between NOI administrations varied. The final administration for each group was on the same day (the start of the NOI administrations varied) and responses were measured 1 week and 3 weeks after completion of the administrations. The 3-week sampling was added to minimize the effect that the different schedules had on the timing of administrations. For example, animals getting 4 NOI administrations with a 6-day interval between administrations had an 15 18 days time interval between the first and fourth administration whereas animals with the 0 time interval between administrations would have had all shots on day 18.

##### Results

20 The results in Figures 4A and 4B show the cellular responses as measured by an ICP27 specific CD8 IFN-gamma ELISPOT. The time between NOI administrations is labelled on the graph. All animals received 4 shots in total. It is clear that the results from the multi gene plasmid (PJV7630) paralleled the results from the initial experiments using the single gene plasmid (ICP27). In this regard, the 4 and 6-day time intervals between 25 administrations gave optimal response in terms of ELISPOT measurements (see Figure 3C) and this held at 3 weeks but responses had dropped about 3 fold by that time (see Figure 3D).

#### EXAMPLE 5

30 The purpose of this experiment was to determine to determine if there is any synergy between the use of genetic adjuvants and clustered NOI administration schedule in enhancing humoral and cell mediated immune (CMI) responses to a relatively weak antigen such as HIV-1gp120.

### Method

This experiment involves the administration of at least two administrations of the gp120 antigen in mice in which each “administration” is made up of a cluster of 1 to 4 XR1 administrations. See schematic diagram below in Figure 5A. In addition, the resting period 5 between administrations is one week. An LT A+B genetic adjuvant ((pPJ2012) was used. A map of the pPJ2012 plasmid is provided in Figure 10. The pPJ2012 plasmid was prepared by cloning the LT genes encoding the LTA and LTB subunit proteins into plasmids pPJ2004 and pPJ2005 respectively as described in WO 03/004055. The genes encoding the LTA and the LTB subunit proteins were then cut from the original 10 plasmids and inserted into a single plasmid to make the pPJ2012 plasmid.

### Results

Figure 5B shows data obtained from animal groups with a 7 day time interval between NOI 15 administrations. The number of XR1 administrations in each cluster was varied as was the presence or absence of the LT A+B genetic adjuvant ((pPJ2012). The results obtained indicate that the presence or absence of the genetic adjuvant had the strongest influence on 20 cellular responses (IFN-gamma production). Figure 5B clearly demonstrates that the LT-enhanced responses were strongest when the NOI administration schedule was clustered into two administrations. These results demonstrate that the clustered administration schedule makes a significant contribution to the overall cellular response obtained with the genetic LT adjuvant.

Figure 5C demonstrates that, in contrast to the CMI response, clustered administrations 25 were shown to have the greatest impact on the strength of total antibody responses. As illustrated in Figure 5C, very strong gp120-specific titers (5-10-fold higher than previously encountered) were elicited using 4 administrations per cluster with and without the genetic adjuvant vector. Importantly, the presence of the genetic adjuvant influenced the balance in the IgG1-to-IgG2a subclasses, but was not required to elicit strong antibody titers (not shown).

**Summary**

The results demonstrate that when an NOI encoding a weak antigen is co-administered with an NOI encoding an adjuvant, then the maximum CMI response in terms of Interferon gamma release is obtained after two NOI administrations.

5 In contrast, a strong humoral immune response is obtained either with or without adjuvant with a cluster of four NOI administrations with a time interval of about 48 hours between administrations.

**EXAMPLE 6**

10 The purpose of this experiment was to determine if immunization of domestic pigs with pPJ7630 would generate cellular immune responses as judged by IFN- $\gamma$  ELISPOTs and DTH responses.

**Method**

15 For this experiment domestic pigs were administered with either pPJ7630 or a placebo (gold alone) by the XR1 device. Pigs were administered with two doses for each immunization and had a cluster schedule of 4 immunizations over a one week period. Thus each pig was given a total of 8 doses of vaccine in a cluster. A second cluster immunization was initiated 28 days after the end of the first cluster.

20

**Results**

Figure 6A shows IFN- $\gamma$  ELISPOT data obtained from animals following the first cluster immunization. Values are the means from 8 immunized animals and 8 control animals. The data shows that the cluster immunization schedule was able to raise cellular immune 25 responses in domestic pigs which are considered to be a difficult model for measuring immunogenicity. The control pigs all showed background levels of ELISPOTs.

Figure 6B shows the average area of erythema present at the site of antigen administration in pigs (4 animals) immunized with pPJ7630 (control animals are not included on the graph). The antigens were given 7 days after the immunizations were complete and the pigs had received two cluster immunizations. The presence of the erythema 48 hours after administration of antigen indicates that this is a DTH reaction. The results show that the 30

DTH response is antigen specific as the null plasmid (N) or an irrelevant antigen (sAg) the Hepatitis B surface antigen plasmid do not induce the DTH reaction, whereas plasmids expressing the vaccine antigens (0, 4, 22, 27) show good DTH responses. In pigs given placebo only (data not shown), no DTH reactions were found for any of the antigens

5 verifying that the responses in 6B are the result of immunization with pPJ7630. At sites where protein extracts were injected there were several good DTH measures for the ICP22 and ICP4 proteins, but none for the control PBS solution and the ICP0 and ICP27 proteins. Because only 5 µg of protein extract was available for injection, and up to 100 µg may be used to elicit a DTH response, the low response may be related to the administered dose.

10

#### Summary

In the domestic pig model a cluster immunization was found to be able to induce cellular immune responses against the vaccine antigens. The domestic pig is not considered to be a good model for raising immune responses but the cluster immunization had the ability to

15 raise cellular immune responses.

#### EXAMPLE 7

A domestic pig study was carried out to examine effect of dosing and device on the antibody response to the ha protein expressed from pPJ1671 as detailed in Table 1 below.

20 (The XR particle acceleration device is described above).

**Table 1**

Cohort (Animal numbers)	Vaccine	Number of Shots
1 (1-8)	pPJ1671 Gun # 49 0.5 mg Au/shot	2
2 (9-16)	pPJ1671 XR-2 11/16 1.5 mg Au/shot	2
3 (17-24)	pPJ1671 XR-2 11/16 1.5 mg Au/shot	1
4 (25-32)	pPJ1671 XR-2 11/16 1.0 mg Au/shot	1
5 (38-40)	pPJ1671 XR-2 11/16 Cluster immunization* 1.5 mg Au/shot	2 X 4
6 (41-48)	pPJ1671 XR-2 11/16 1.5 mg Au/shot	8
7 (49-56)	Negative Control	

\*2 shots on alternating days (Days 1,3, 5 and 8)

5 Animals were primed and boosted with vaccines at 4 weeks. Blood was taken at various time points and graphed below are antibody titers 2 weeks after the boost. Two groups were given a total of 8 doses at each immunization, either by cluster or all at one time. The animals immunized with cluster had a higher level of serum antibody.

10 Antibody titers  
 Antibody titers were measured by an ELISA following standard procedures using 200 hemagglutination units/well of Sarkosyl-disrupted purified Sw/IN virus diluted in phosphate-buffered saline. The swine antibodies were measure directly by using a goat anti-swine immunoglobulin G alkaline phosphatase conjugate.

**Plasmid pPJ1671**

Plasmid pPJ1671, as shown in Figure 8, is a human DNA vaccine vector encoding the hemagglutinin (HA) antigen of influenza A/Panama/2007/99 (H3N2). The HA coding sequence was obtained by a standard reverse transcriptase / polymerase chain reaction (RT-PCR) cloning technique using a sample of A/Panama/2007/99 virus obtained from the CDC as a source of template RNA. The following steps were employed in developing the final pPJ1671 HA DNA vaccine vector:

- RT-PCR production of dsDNA fragment of RNA segment #4 of A/Panama/2007/99 (H3N2).
- Propagation of RNA segment #4 DNA clone in a standard pUC19-based vector in *E. coli*.
- Sequence analysis of the H3 Panama HA coding sequence within the RNA segment 4 clone.
- A second PCR reaction to generate a DNA fragment containing the H3 Panama coding sequence (without its ATG codon) with ends compatible with the pPJ17563 DNA vaccine vector (Nhe I and Bsp 120I).

Insertion of the H3 Panama HA coding sequence into pPJ17563 yielding the final pPJ1671 H3 Panama HA DNA vaccine vector that conform to the Kozak consensus. Use of the vector-supplied ATG codon (via insertion at the Nhe I site) results in a minor 2-amino acid insertion at the amino terminus of the coding sequence of the HA gene as depicted in Figure 9.

**Summary**

This study demonstrates that cluster immunisation significantly improved the antibody response in a domestic pig model.

**Plasmid pPJ7563****Construction of pPJ7563**

A pPJ7563 plasmid map is provided in Figure 11.

The base composition for the pPJ7563 plasmid is provided in Figure 12.

5 The components and their position in the plasmid *pPJ7563* are as follows:

1-44 Transposon 903 sequences

45-860 Kanamycin resistance coding sequence from Transposon 903

861-896 Transposon 903 sequences

897-902 Sal1 site

10 903-1587 CMV promoter

1588-1718 untranslated leader sequence from the immediate-early gene of CMV

1719-1724 Fusion of BamH1 and BglII restriction enzymes

1725-1857 Rat insulin intron A

1858-1863 BamH1 site

15 1864-1984 HBV surface antigen 5'- untranslated leader

1985-1993 Synthetic start codon/ Nhe1 cloning site

1994-2011 Synthetic cloning sites

2012-2544 HBV enhancer

2545-2555 Old vector sequence. No hits against NCBI databases

20 2556-2686 Rabbit beta-globin polyadenylation region

2687-3759 pUC19 vector sequence

The pPJ7563 plasmid was prepared as follows:

**Description of Figure 13, flowchart outlining the construction of PJV7563:**

25 The bovine growth hormone polyadenylation signal (BGH<sub>p</sub>A) in pWRG7074 was replaced by the rabbit beta-globulin polyadenylation signal (RBG<sub>p</sub>A), resulting in pWRG7284. The intron A of CMV was removed from pWRG7284 by replacing all the CMV sequences with a pWRG7128 derived PCR fragment containing the CMV promoter and exon1/ 2 fusion. This resulted in pWRG7293.

The CMV and HBV sequences were removed from pWRG7284 and replaced with the CMV and 5'-HBV sequences from pWRG7293 and the 3'-HBV sequences from pWRG7128. The SIV nef gene sequence was removed at this step, resulting in pPJ7382. pPJ7382 was further engineered by adding the rat insulin intron A (RIA) to create 5 pPJ7389. The Kanamycin resistance (Kan<sup>R</sup>) gene in pPJ7389 was replaced with a shortened version to remove unneeded sequences from both ends of this gene, resulting in pPJ7496. The Nhe 1site in the RIA was cured from pPJ7496, yielding pPJ7530.

10 The HBV sequences through the 5' region of the 3'-UTR in pPJ7530 were removed and replaced by the HBV 5'-UTR, flu M2 gene and the 5'-region of the 3'-UTR from pPJ7468, yielding PJV7549. PJV has determined that retention of the HBVenh and HBV 5' UTR regions from WRG7128 in vectors encoding a variety of antigens can reproducibly improve both antigen expression and immunogenicity. These are now common elements in PJV's DNA vaccine vectors. The M2 gene was then deleted from pPJ7549 and replaced 15 by oligonucleotides that formed a polylinker. This manipulation yielded pPJ7563, an expression vector that is able to accept other coding sequences.

#### Construction of Plasmid pWRG7074, Parent Vector of PJV7563

20 A standard plasmid backbone, pWRG7074 was developed. This backbone was used as the precursor plasmid from which to engineer pWRG7128, the HBsAg expression vector used in several clinical trials. In this section, the derivation of this backbone is described in narrative and shown in Figures 15 AND 16 , "Flowchart Derivitization of Plasmids PJV7074 and PJV7128" and "Key Plasmid Feature Maps", respectively. Briefly, pWRG7074 was derived by insertion of a single fragment containing the human CMV 25 immediate early promoter and bovine growth hormone polyadenylation sequence into the standard, well characterized pUC19 bacterial plasmid vector. Several subsequent manipulations were employed to replace the ampicillin with a Kanamycin (Kan<sup>R</sup>) resistance marker and to alter some restriction sites. The DNA fragment that was the source of the CMV promoter and bGH poly A region was obtained from plasmid pJW4303, a gift from 30 Jim Mullins who was then at Stanford University.

Detailed narratives concerning the construction of plasmids WRG7074 and WRG7128 are given below. Unless noted otherwise, all cloning was performed at PowderJect Vaccines, Inc., Madison, WI (and formerly known as Agracetus, Inc., Auragen, Inc., or Geneva, Inc. Middleton, WI). Construction steps are in *italics*. Bullet points supply factual information 5 regarding specific sequences.

Step 1: The small HindIII-BamHI fragment of pJW4303 (map, Figure 10.2) containing the TPA signal peptide coding sequence was deleted by HindIII-BamHI digestion. This small fragment was replaced with a HindIII-NotI-BamH1 linker to generate JW4303-NotI.

10

The fragment containing the CMV promoter and bGH poly A region from pJW4303 is a Sal I – Xho I fragment that PJV has since determined to be 2131 bp in length. The nucleotide sequence for the Sal I – Xho I fragment derived from pJW4303 has been deduced. The following items are identified in Figure 10.2:

15

- Sal I site at nucleotide position 1 of the fragment
- Start of CMVIE promoter fragment at nucleotide position 7. This corresponds to nucleotide position 451 from GenBank sequence accession #M60321 (human cytomegalovirus immediate early protein gene 5'end).
- End of CMVIE promoter fragment at nucleotide position 1648. This corresponds to nucleotide position 2097 from GenBank sequence accession #M60321 (human cytomegalovirus immediate early protein gene 5'end). It should be noted that a few nucleotide differences were observed between the deduced CMVIE promoter region and the above mentioned GenBank sequence. This is likely due to natural polymorphisms between different CMV virus isolates.
- ATG translation initiation codon at nucleotide position 1661 for the signal peptide coding sequence of human tissue plasminogen activator. The TPA signal peptide coding sequence was derived from synthetic DNA as described by Lu et al. (J. Virol. 70:3978, 1996). The Lu et al. publication briefly describes the construction of pJW4303, but this description contains some errors that are not consistent with the deduced sequence.

20

25

30

- Coding sequence insertion sites Hind III and Nhe I at nucleotide positions 1649 and 1724, respectively. Note that the SIV nef homology region is shown as part of the bGHpA region.
- Bam HI restriction site at nucleotide position 1741 that begins the region of homology to SIV nef. This corresponds to nucleotide position 9444 of GenBank sequence accession #M33262 (simian immunodeficiency virus, isolate 239, complete proviral genome and flanking sequence).
- Bgl II restriction site at nucleotide position 1849 that terminates the SIV nef homology region. This corresponds to nucleotide position 9552 of GenBank sequence accession #M33262 (simian immunodeficiency virus, isolate 239, complete proviral genome and flanking sequence).
- In 1999 it was discovered that a sequence representing 109 base pairs homologous with a sequence of the Simian Immunodeficiency Virus nef gene sequence, was present in this vector. As shown in Figure 10.1, this sequence had been removed at the time pWRG7128 was constructed. However, it remained in pWRG7074. This sequence was present in pWG4303 and derivatives through pWRG7077 and pWRG7074. The SIV nef homology is found between nucleotide positions 77 and 184. Thus, the insertion of the SIV nef fragment adjacent to the bHG poly A region was an apparent construction artifact that occurred prior to PJV's receipt of the source DNA.
- Start of bovine growth hormone poly A region homology at nucleotide position 1873. This corresponds to nucleotide position 2326 of GenBank sequence accession #M57764 (bovine growth hormone gene, complete coding sequence).
- End of bovine growth hormone poly A region homology at nucleotide position 2096 of Attachment 4. This corresponds to nucleotide position 2550 of GenBank sequence accession #M57764 (bovine growth hormone gene, complete coding sequence).
- Xho I restriction site at the end of the fragment (nucleotide position 2131).

30 Step 2: Insertion of the CMV promoter and bGH poly A fragment from pJW4303-NotI (SalI-XhoI fragment) into the Sal I site of pUC19 yielding plasmid pWRG7012 (figure below).

pWRG7012 contains two BamHI sites and two HindIII sites. One of each of these sites were removed in subsequent steps (see below).

Step 3: Deleted the EcoR1-Xba1 region of pWRG7012 to remove a large section of 5 pUC19's multiple cloning site, to generate pWRG7013 (Figure 10.2).

pWRG7013 retains two HindIII sites but has only one BamHI site.

Step 4: Removed the HindIII site, located 5' of the CMV promoter, from pWRG7012 to 10 allow easy utilization of the HindIII site between the intron and downstream inserts. This generated pWRG7014 (Figure 10.2).

pWRG7014 retains two BamHI sites but has only one HindIII site.

15 Step 5: To yield a plasmid containing only 1 HindIII site and 1 BamHI site, the HindIII-EcoR1 fragment from pWRG7013 was placed into HindIII-EcoR1 deleted pWRG7014 to generate pWRG7020, the ampicillin resistant version of WRG7077 (Figure 10.2).

Step 6: Deleted the Eam1105 1-Pst1 flanked ampicillin resistance gene in pUC19. Blunt-ended the fragment containing the origin of replication by treatment with polymerase. 20 Isolated the Pst1 flanked kanamycin resistance gene in PUC4K. This fragment was blunt-ended by treatment with polymerase and ligated to the origin of replication fragment. This generated pWRG7072, a KanR vector that could accept the CMV-HBsAg-bGH-pA cassette from pWRG7031 (Step 8).

25 Step 7: Deleted the Hd3-BamH1 sequences of the polylinker in pWRG7020 and blunt-ended the vector with polymerase. Isolated the BamH1 flanked 1.4KB HBsAg containing fragment in pAM6. This fragment was blunt-ended by treatment with polymerase and ligated into the vector. This yielded pWRG7031, an ampicillin resistant HBsAg expression 30 plasmid.

Step 8: Deleted the Pvu2- Sph1 sequences of pWRG7072. Cut pWRG7031 with EcoR1, blunt-ended the site with polymerase, and further cut the plasmid with Sph1 and isolated

the fragment containing the CMV, HBV, and bovine sequences. This fragment was ligated into the prepared pWRG7072 to yield pWRG7074.

Step 9: Cut pWRG7074 with Bgl2, blunt-ended with polymerase, and further cut with BstX1 to make a vector fragment. pWRG7074 was cut with Nco1, blunt-ended with mung bean nuclease, and further cut with BstX1 to make an insert fragment containing the 3'-enhancer. The ligation of these two fragments resulted in pWRG7128, a HBsAg expression plasmid devoid of the 5'-coding region of the HbxAg and the SIV NEF sequence found in pWRG7074.

10

Step10: Construction of pWRG7077: Cut pWRG7072 with Sap1, blunt-ended with polymerase, and further cut with Sph1 to generate a fragment containing the origin of replication and kanamycin resistance gene. Cut and blunt-ended the EcoR1site in WRG7020, then partially cut with Sph1 to generate a fragment containing the CMV promoter, intron A, and BGH polyadenylation region. These fragments were ligated together to generate pWRG7077. The final vector pWRG7077 contains the original CMV-intron A-bGH-pA region derived from the source plasmid pJW4303 except with the alteration described in step 1 in which the TPA signal peptide coding sequence was replaced with a linker containing a Not I restriction site.

20

#### EXAMPLE 8

Balb/c mice are vaccinated against HIV antigens encoded by a plasmid nucleic acid. The plasmid expresses codon optimised gag, codon optimised RT and Nef driven by an HCMV IE promoter that is devoid of intron A. Gold particles coated with the plasmid are prepared as described in above in the General Techniques section. 0.5 ug of plasmid (in the form of coated particles) are administered to the abdomen of the mice using a PowderJect XR instrument (PowderJect Vaccines, Inc, Madison) in the form of a single shot. Multiple administrations are carried out at different time points in different mice, for example on days 0, 2, 4 and 7.

30

The mice are sacrificed 3 days after the final administration. Single cell suspensions are obtained from the mouse spleens as described in the General Techniques section. Cells are cultured in the presence of an HIV CD8 T cell epitope.

5 The level of the CD8 T cell response stimulated by administration of the plasmid is measured using the INF-( ELISPOT assay described in the General Techniques section.

**EXAMPLE 9**

We prepared copies of E6 and E7 by PCR from an HPV 16 genomic clone obtained from 10 ATCC. The full length plasmid is maintained under BSL-2 conditions since it contains a complete viral genome. We detoxified E6 and E7 by deleting the binding regions for p53 and Rb respectively (Slebos et al., Virol. 1995, 208, 111-120; and Šmahel et al., Virol. 2001, 281, 231-238). PCR fragments were cloned into PJV7563 placing the genes under control of the CMV promoter without intron A.

15 Plasmids were prepared by Qiagen endotoxin free Mega kits and coated onto gold particles at 2 ug DNA per mg gold using the standard spermidine  $\text{CaCl}_2$  method. Cartridges were prepared using 0.05 mg/ml PVP. B6 mice were immunized with single deliveries on the shaved abdomen using an XR research device at 500 psi.

20 TC-1 cells were obtained from Johns Hopkins School of Medicine. Cells were expanded in culture for a minimum number of passages and vials were then frozen and stored in liquid  $\text{N}_2$  until use. Cells were prepared for injection in PBS. Anesthetized mice were injected subcutaneously with between  $2 \times 10^4$  to  $2 \times 10^5$  cells in 50 to 100  $\mu\text{l}$  on the shaved right 25 flank. Tumors were measured Mon., Wed., and Fri. beginning at day 7. Two diameter measurements at right angles were taken and multiplied to produce a square area. The health of the animals was also monitored. Mice were euthanized if tumors grew to greater than  $120 \text{ mm}^2$ , if tumors appeared necrotic, or mice appeared moribund.

30 For ELISPOT assays, mice were sacrificed one week after last immunization. Spleens were removed aseptically and single cell suspensions were prepared. Cells were plated at 1  $\times 10^6$  or  $5 \times 10^5$  cells per well in BD (-IFN ELISPOT kits according to manufacturers instructions. Peptides specific for E7 CD4 and CD8 and E6 CD8 were added at a final

concentration of 10 uM. Media wells contained equivalent amounts of DMSO as wells containing peptide. Specific spots were calculated by subtracting media spots from those induced in the presence of peptide.

5 Results

Immunization of B6 mice with either E6 or E7 DNA leads to the induction of significant numbers of (-IFN secreting cells (Figure 23). In the case of E6, only a CD8-specific epitope is known. In the case of E7, both CD4- and CD8-specific epitopes have been identified and strong responses to both are seen after PMED immunization. Addition of 10 either *E. coli* heat labile toxin (LT) or cholera toxin (CT) DNA to the E6 or E7 vaccines was tested. While LT increased (-IFN ELISPOT responses to E7 peptides approximately two-fold (Figure 23), no increase in tumor protection was seen with either toxin.

Interestingly, injection of TC-1 cells alone, induces (-IFN responses to E6 and E7 (Figure 15 24). These are lower than that observed with PMED immunization of three doses delivered in a cluster three days apart. Combining TC-1 injection with PMED immunization leads to an intermediate result.

20 Injection of  $5 \times 10^4$  TC-1 cells leads to consistent and rapid development of tumors in untreated B6 mice. Prophylactic treatment with as little as one dose of either E6 or E7 DNA provides substantial protection against tumor development (Figure 25). Therapeutic immunization with either E6 or E7 is also effective if delivered as a cluster of three doses beginning on day 3 after tumor injection (Figure 26). Delivery of fewer doses is less effective (data not shown). Co-delivery of E6 and E7 plasmids was not more effective than 25 either one alone, although this has only been tested once so far.

30 In one study, animals that were protected against an initial TC-1 challenge by E6 vaccination (Figure 26) were rechallenged 50 days later without further treatment. As shown in Figure 27, all animals were completely protected against this second challenge while all of the age-matched untreated controls developed tumors and were euthanized.

We have attempted treatment of larger tumors with varying degrees of success. For example, as shown in Figure 28, treatment with a cluster of three doses of E6 DNA beginning at  $20\text{ mm}^2$  led to regression in 5 of 5 mice while treatment beginning at  $35\text{ mm}^2$  caused only a slight delay in tumor growth followed by rapid progression.

5



The data presented above indicate that detoxified E6 and E7 DNA elicit a strong T cell response against the respective peptide epitopes when delivered to B6 mice. Furthermore, these responses largely correlate with the ability of the vaccines to inhibit the growth of TC-1 tumor cells. Such treatment is effective as either prophylaxis or therapy.

10

## OVERALL SUMMARY

The present invention provides a method or process for enhancing the CMI response *in vivo*. This approach provides a practical tool to enhancing the CMI response to an NOI encoding at least one EOI of a TA by inducing early enhanced T-cell activity over a 5 relatively short period of time. The invention is based on the surprising finding that at least two administrations of an NOI encoding at least one EOI of a TA at intervals of from about 48 hours to about 144 hours between administrations significantly amplify the CMI response to at least one EOI of a TA. The finding that the NOI administration regime is so effective at eliciting an early enhanced CMI response is completely unexpected and 10 contrary to the perceived wisdom in the field that a relatively longer time interval between immunisations (typically in terms of weeks rather than days) is required to elicit an enhanced CMI response. The enhanced CMI response may be used prophylactically and therapeutically to immunomodulate the CMI response to one or more EOI of a TA. The time course of the induced CMI response enables an effective strategy to be developed for 15 immunotherapy of pre-existing T cell mediated disorders as well as facilitating broad protection against subsequently encountered antigens. The present invention also provides a rapid method for the identification of candidate agents capable of enhancing or modulating a CMI response. This assay method is broadly applicable to both screening and vaccination, and is relevant to the development of prophylactic and/or therapeutic vaccines 20 using the identified candidate agents.


All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the 25 invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be covered by the present invention.

**Fig 1A (ICP27 plasmid)****Fig 1B (PJV7630)**

Title: Method

Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151


Fig 2A



Title: Method


Inventor(s): Ralph Patrick BRAUN et al.

DOCKET NO.: 036481-0151


**Fig 2B.**

Title: Method

Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151


**Fig 2C**

**Figure 3A**



Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151


**Figure 3B**





Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 3C**

**Antibody Titer for sAg cluster**



Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 4A****Figure 4B**

**Figure 5A**




Figure 5B






Figure 5C




Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 6A**




**Figure 6B**




Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

Figure 7




Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 8**




Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151


**Figure 9**



**Title: Method**  
**Inventor(s): Ralph Patrick BRAUN et al.**  
**DOCKET NO.: 036481-0151**

**Figure 10**

Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 11**

Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 12**

Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

**Figure 13**  
**Flowchart Derivitization of Plasmids PJV7563**










Figure 14 (i) – (viii)





## Feature Maps of Key Plasmids in Construction of pPJ7563

















**Figure 15**  
**Flowchart Derivation of Plasmids WRG7074 and WRG7128**




**Figure 16 (i) to (v): Key Plasmid Features**


Title: Method  
 Inventor(s): Ralph Patrick BRAUN et al.  
 DOCKET NO.: 036481-0151




**WRG7012**




**WRG7013**






Title: Method  
 Inventor(s): Ralph Patrick BRAUN et al.  
 DOCKET NO.: 036481-0151




Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151



Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

Figure 17



Title: Method  
 Inventor(s): Ralph Patrick BRAUN et al.  
 DOCKET NO.: 036481-0151

Figure 18

## Sequence of p55 gag insert in pGagOptpr2

5 ATGGGTGCCGAGCTCCGTACTGTCTGGTGGAGAGCTGGACAGATGGGAGAAAATTAGGCT  
 GCGCCGGGAGGCAAAAAGAAATACAAGCTCAAGCATATCGTGTGGCCTCGAGGGAGCTG  
 AACGGTTGCCGTGAACCCAGGCCTGCTGGAAACATCTGAGGGATGTCGCCAGATCCTGGG  
 CAATTGAGCCATCCCTCCAGACGGGAGTGAAGAGCTGAGGTCTTGTATAACACAGTGGC  
 TACCCCTCTACTGCGTACACCAGAGGATCGAGATTAAAGGATACCAAGGAGGCCCTGGACAAA  
 10 TTGAGGAGGAGCAAAACAAGAGCAAGAAGAAGGCCAGCAGGCAGCTGCTGACACTGGCAG  
 AGCAACCAGGTATCACAGAACTATCCTATTGTCCAAAACATTCAAGGCCAGATGGTTCATCA  
 GGCCATCAGCCCCGGACGCTCAATGCCCTGGTGAAGGTTGTCGAAGAGAAGGCCCTTCTC  
 CTGAGGTTATCCCCATGTTCTCCGCTTGAGTGAGGGGCCACTCCTCAGGACCTCAATACA  
 ATGCTTAATACCGTGGCGGCCATCAGGCCCATGCAAATGTTGAAGGAGACTATCAACGA  
 15 GGAGGCAGCCGAGTGGGACAGAGTGCATCCCGTCCACGCTGGCCAATCGGCCCGGACAGA  
 TGCGGGAGCCTCGCGCTCTGACATTGCCGGCACACCTCTACACTGCAAGAGCAAATCGGA  
 TGGATGACCAACAATCCTCCCATCCAGTTGAGAAATCTATAAACGGTGGATCATTCTCGG  
 TCTCAATAAAATTGTTAGAATGTAATGACTCTCCGACATCCATCCTTGACATTAGACAGGGACCCA  
 AAGAGCCTTTAGGGATTACGTCGACGGTTTATAAGACCTGCGAGCAGAGCAGGCCCT  
 20 CAGGAGGTCAAAACTGGATGACGGAGACACTCCTGGTACAGAACGCTAACCCGACTGCAA  
 AACAAATCTGAAGGCACTAGGCCGGCTGCCACCTGGAAGAGATGATGACGCCCTGTCAGG  
 GAGTAGGCGGACCCGGACACAAAGCCAGAGTGTGGCCGAAGCCATGCCAGGTGACGAAC  
 TCCGCAACCATCATGATGCAAGAGAGGGAACTCCGCAATCAGCGGAAGATCGTAAGTGT  
 CAATTGCGGCAAGGAGGGTCATACCGCCCGCAACTGTCGGGCCCTAGGAAGAAAGGGTGT  
 25 GGAAGTGCAGCAAGGAGGGACACCAAGATGAAAGACTGTACAGAACGACAGGCCAATTTCTT  
 GGAAAGATTTGGCCGAGCTACAAGGGAGACCTGGTAATTCTGCAAAAGCAGGCCAGGCC  
 CACCGCCCCCTGAGGAATCCTCAGGTCCGGAGTGGAGACCACAACGCCCTCCCCAAAAC  
 AGGAACCAATCGACAAGGAGCTGTACCCCTTAACCTCTCGCTCTGGCAACGAC  
 CCGTCGTCTCAATAA  
 30 MGARASVLSG GELDRWEKIR LRPGGKKYK LKHIVWASRE LERFAVNPL  
 LETSEGRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA  
 LDKIEEEQNK SKKKAQQAAA DTGHSNQVSQ NYPIVQNIQG QMVHQAIISPR  
 TLNAWVKVVE EKAESPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAQM  
 35 LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEIQIGWM  
 TNNPPIPVGE IYKRWIILGL NKIVRMYSP SILDIRQGPK EPFRDYVDRF  
 YKTLRAEQAS QEVKNWMET LLVQNANPDC KTIILKALGPA ATLEEMMTAC  
 QGVGGPGHKA RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH  
 TARNCRAPRK KGCWKGKREG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ  
 40 SRPEPTAPPE ESFRSGVETT TPPQKQEPID KELYPLTSR SLFGNDPSSQ  
 \*

Title: Method

Inventor(s): Ralph Patrick BRAUN et al.

DOCKET NO.: 036481-0151

Figure 19

## Sequence of the p17/24trNEF insert in p17/24trNEF1

5 ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTT  
 AAGGCCAGGGGGAAAGAAAAAATATAAATTAAACATATAGTATGGCAAGCAGGGAGCTAG  
 AACGATTCGCAGTTAACCTGGCTGTTAGAACATCAGAAGGCTGTAGACAAATACTGGGA  
 CAGCTACAACCATCCCTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGC  
 AACCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTAGACAAGA  
 10 TAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGACAC  
 AGCAATCAGGTCAGCCAAAATTACCCCTATAGTGCAGAACATCCAGGGGCAAATGGTACATCA  
 GGCCATATCACCTAGAACCTTAAATGCATGGTAAAAGTAGTAGAGAGAAGGGCTTCAGCC  
 CAGAAGTGTACCCATGTTTCAGCATTATCAGAAGGAGCCACCCACAAGATTAAACACC  
 ATGCTAAACACAGTGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGA  
 15 GGAAGCTGCAGAATGGGATAGAGTCATCCAGTCATGCCAGGGCTATTGCACCAGGCCAGA  
 TGAGAGAACCAAGGGGAAGTGACATAGCAGGAACACTACTAGTACCCCTCAGGAACAAATAGGA  
 TGGATGACAAATAATCCACCTATCCCAGTAGGAGAAATTATAAAAGATGGATAATCCTGGG  
 ATTAATAAAATAGTAAGAATGTATAGCCCTACAGCATTCTGGACATAAGACAAGGACCAA  
 AAGAACCTTTAGAGACTATGTAGACCGGTTCTATAAAACTCTAAGAGCCAGCAAGCTCA  
 20 CAGGAGGTAAAAAATTGGATGACAGAACCTTGTGGTCCAAATGCGAACCCAGATTGAA  
 GACTATTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATGTCAGG  
 GAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTGGTGGGTTTCCAGTCACACCTCAGGTA  
 CCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTAGCCACTTTAAAAGAAAAGGG  
 GGGACTGGAAGGGCTAATTCACTCCCAAAGAACAGACAAGATATCCTGATCTGGATCTACC  
 25 ACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAAGATATCCA  
 CTGACCTTGGATGGTGTACAAGCTAGTACCGAGTTGAGCCAGATAAGGTAGAAGAGGCCAA  
 TAAAGGAGAGAACACCAGCTTGTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGA  
 GAGAAGTGTAGAGTGGAGGTTTGACAGCCACCTAGCATTACACGTGGCCGAGAGCTG  
 CATCCGGAGTACTTCAAGAACTGCTGA  
 30 MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPL  
 LETSEGRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA  
 LDKIEEEQNK SKKKAQQAAA DTGHSNQVSQ NYPIVQNIQG QMVHQAIISPR  
 TLNAWVKVVE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM  
 35 LKETINEEEA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEIQIGWM  
 TNNPPIPVGE IYKRWIIILGL NKIVRMSPT SILDIRQGPK EPFRDYVDRF  
 YKTLRAEQAS QEVKNWMET LLVQNANPDC KTIKLALGPA ATLEEMMTAC  
 QGVGGPGHKA RVLVGFVTP QVPLRPMTYK AAVDLSHFLK EKGGLEGLIH  
 SQRRQDILDL WIYHTQGYFP DWQNYTPGPG VRYPLTFGWC YKLVPVEPDK  
 40 VEEANKGENT SLLHPVSLHG MDDPEREVLE WRFDSHLAFH HVARELHPEY  
 FKNC\*

Title: Method

Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151


Figure 20

## Sequence of the p17/24opt/trNef insert in p17/24opt/trNef1

5 ATGGGTGCCGAGCTCCGTACTGTCTGGTGGAGAGCTGGACAGATGGGAGAAAATTAGGCT  
 GCGCCCGGGAGGCAAAAGAAATACAAGCTCAAGCATATCGTGTGGCCTCGAGGGAGCTTG  
 AACGGTTGCCGTGAACCCAGGCCTGCTGGAAACATCTGAGGGATGTCGCCAGATCCTGGGG  
 CAATTGCAGCCATCCCTCCAGACCGGGAGTGAAGAGCTGAGGTCTGTATAACACAGTGGC  
 TACCTCTACTGCGTACACCAGAGGATCGAGATTAAGGATACCAAGGAGGCCCTGGACAAAA  
 10 TTGAGGAGGAGCAAAACAAGAGCAAGAAGAAGGCCAGCAGGCAGCTGCTGACACTGGCAT  
 AGCAACCAGGTATCACAGAACTATCCTATTGTCCAAACATTAGGGCCAGATGGTTCATCA  
 GGCCATCAGCCCCGGACGCTCAATGCCCTGGGTGAAGGTTGTCGAAGAGAAGGCCCTTC  
 CTGAGGTTATCCCCATGTTCTCCGCTTGAGTGAGGGGCCACTCCTCAGGACCTCAATACA  
 ATGCTTAATACCGTGGCGGCCATCAGGCCCATGCAAATGTTGAAGGAGACTATCAACGA  
 15 GGAGGCAGCCGAGTGGGACAGAGTCATCCCGTCCACGCTGGCCAATCGGCCCGGACAGA  
 TGCAGGGAGCCTCGCGCTCTGACATTGCCGACACCACCTCTACACTGCAAGAGCAAATCGGA  
 TGGATGACCAACAATCCTCCCATCCCAGTTGAGAAATCTATAAACGGTGGATCATTCTCGG  
 TCTCAATAAAATTGTTAGAATGACTCTCCGACATCCATCCTTGACATTAGACAGGGACCCA  
 AAGAGCCTTTAGGGATTACGTCGACCGGTTTATAAGACCCTGCGAGCAGAGCAGGCCCT  
 20 CAGGAGGTCAAAACTGGATGACGGAGACACTCCTGGTACAGAACGCTAACCCGACTGCAA  
 AACAACTTGAAGGCACTAGGCCCGCTGCCACCTGGAAGAGATGATGACCGCCTGTCAGG  
 GAGTAGGCGGACCCGGACACAAAGCCAGAGTGGTGTGGGTTTCCAGTCACACCTCAG  
 GTACCTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTAAAAGAAAA  
 GGGGGGACTGGAAGGGCTAATTCACTCCAAAGAACAGAACAGATATCCTGATCTGTGGATCT  
 25 ACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGTCAGATAT  
 CCACTGACCTTGGATGGTGTACAAGCTAGTACCACTGAGCCAGATAAGGTAGAACAGGGC  
 CAATAAAGGAGAGAACACCAGCTTACACCCCTGTGAGCCTGCATGGATGGATGACCCGG  
 AGAGAGAAGTGTAGAGTGGAGGTTGACAGCCACCTAGCATTACACGTGGCCGAGAG  
 CTGCATCCGGAGTACTTCAAGAACGTGCTGA  
 30 MGARASVLSG GELDRWEKIR LRPGGKKYK LKHIVWASRE LERFAVNPGL  
 LETSEGRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA  
 LDKIEEEQNK SKKKAQQAAA DTGHSNQVSQ NYPIVQNIQG QMVHQAIISPR  
 TLNAWVKVVE EKAESPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM  
 35 LKETINEEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEIQIGWM  
 TNNPPIPVGE IYKRWIIILGL NKIVRMSPT SILDIRQGPK EPFRDYVDRF  
 YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTIKALGPA ATLEEMMTAC  
 QGVGGPGHKA RVLMVGFPVT PQVPLRPMTY KAAVDSLHFL KEKGGLLELI  
 HSQRQDILD LWIYHTQGYF PDWQNYTPGP GVRYPLTFGW CYKLPVVEPD  
 40 KVEEANKGEN TSLLHPVSLH GMDDPEREVL EWRFDSHLAF HHVARELHPE  
 YFKNC\*

Title: Method

Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151



**Figure 21**  
**Sequence of RT insert of p7077-RT3:**

5


ATGGGCCCATCAGTCCCATCGAGACCGTGCCTGAAAGCTGAAACCCGGGATGGACGGCCC  
 CAAGGTCAAGCAGTGGCCACTCACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCACCG  
 AGATGGAGAAAGAGGGCAAGATCAGCAAGATCGGGCCTGAGAACCCATACAACACCCCCGTG  
 TTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGATTCGGGAGCTGAA  
 10 TAAGCGGACCCAGGATTCTGGGAGGTCCAGCTGGCATCCCCATCCGGCCGGCTGAAGA  
 AGAAGAAGAGCGTGACCGTGCTGGACGTGGCGACGCTACTTCAGCGTCCCTCTGGACGAG  
 GACTTTAGAAAGTACACCGCCTTACCATCCCATCTATCAACAAACGAGACCCCTGGCATCAG  
 ATATCAGTACAACGTCCCTCCCCCAGGGCTGGAGGGCTCTCCGCCATTTCCAGAGCTCCA  
 TGACCAAGATCCTGGAGCCGTTCGGAAGCAGAACCCGATATCGTCATCTACCAAGTACATG  
 15 GACGACCTGTACGTGGCTCTGACCTGGAAATCGGGCAGCAGTCGACGAAGATTGAGGAGCT  
 GAGGCAGCATCTGCTGAGATGGGGCCTGACCCTCCGGACAAGAAGCATCAGAAGGAGCCGC  
 CATTCCGTGGATGGCTACGAGCTCCATCCCGACAAGTGGACCGTGCAGCCTATCGTCCTC  
 CCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTCAACTGGC

**Title: Method**  
**Inventor(s): Ralph Patrick BRAUN et al.**  
**DOCKET NO.: 036481-0151**

}

TAGCCAGATCTATCCCAGGATCAAGGTGCGCCAGCTCTGCAAGCTGCTGCGCGCACCAAGG  
CCCTGACCGAGGTGATTCCCCTCACGGAGGAAGCCGAGCTCGAGCTGGCTGAGAACCGGGAG  
ATCCTGAAGGAGCCCGTGCACGGCGTGTACTATGACCCCTCCAAGGACCTGATGCCGAAAT  
CCAGAACGGCCAGGGCAGTGGACATACCAGATTACCAAGGAGCCTTCAAGAACCTCA  
5 AGACCGGCAAGTACGCCGCATGAGGGGCGCCACACCAACGATGTCAAGCAGCTGACCGAG  
GCCGTCCAGAAGATCACGACCGAGTCCATCGTATCTGGGGAAAGACACCCAAGTTCAAGCT  
GCCTATCCAGAAGGAGACCTGGGAGACGTGGTGGACCGAATATTGGCAGGCCACCTGGATT  
CCGAGTGGGAGTTCGTGAATACACCTCTGGTGAAGCTGTGGTACCAAGCTCGAGAAGGAG  
CCCATCGTGGCGCGGAGACATTACGTGGACGGCGGGCAACCGCGAAACAAAGCTCGG  
10 GAAGGCCGGGTACGTACCAACCGGGGCCAGAAGGTCGTACCCCTGACCGACACCA  
ACCAAGACGGAGCTGCAGGCCATCTATCTCGCTCTCCAGGACTCCGGCTGGAGGTGAAC  
ATCGTACGGACAGCCAGTACCGCTGGCATTATTCAAGGCCAGCCGACAGTCCGAGAG  
CGAACTGGTGAACCAGATTATCGAGCAGCTGATCAAGAAAGAGAAGGTCTACCTGCCTGG  
TCCCGGCCATAAGGCATTGGCGCAACGAGCAGGTCGACAAGCTGGTAGTGCGGGGATT  
15 AGAAAGGTGCTGTAA

MGPISPIETV SVKLKPGMDG PKVKQWPLTE EKIKALVEIC TEMEKEGKIS  
KIGPENPYNT PVFAIKKKDS TKWRKLVDFR ELNKRTQDFW EVQLGIPHPA  
GLKKKKSVTV LDVGDAYFSV PLDEDFRKYA AFTIPSINNE TPGIRYQYNV  
20 LPQGWKGSPA IFQSSMTKIL EPFRKQNPDI VIYQYMDLY VGSDEIGQH  
RTKIEELRQH LLRWGLLTPD KKHQKEPPFL WMGYELHPDK WTVQPIVLPE  
KDSWTVNDIQ KLVGKLNWAS QIYPGIKVRQ LCKLLRGTKA LTEVIPLTEE  
AELELAENRE ILKEPVHGKV YDPSKDLIAE IOKQGQGQWT YQIYQEPFKN  
LKTGKYARMR GAHTNDVKQL TEAVQKITTE SIVIWGKTPK FKLPIQKETW  
25 ETWWTEYWQA TWIPEWEFVN TPPLVKLWYQ LEKEPIVGAE TFYVDGAANR  
ETKLGKAGYV TNRGRQKVVT LTDITTNQKTE LQAIYLALQD SGLEVNIYTD  
SQYALGIIQQA QPDQSESELV NQIIIEQLIKK EKVYLAWVPA HKGIGGNEQV  
DKLVSAGIRK VL\*

**Figure 22****Sequence of the coding insert in p73i-RT3:**

5 ATGGGCCCATCAGTCCATCGAGACCGTCCGGTGAAGCTGAAACCCGGATGGACGGCCC  
 CAAGGTCAAGCAGTGGCCACTCACCGAGGAGAAGATCAAGGCCCTGGAGATCTGCACCG  
 AGATGGAGAAAGAGGGCAAGATCAGCAAGATCGGGCCTGAGAACCCATAAACACCCCCGTG  
 TTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGATTCCGGGAGCTGAA  
 TAAGCGGACCCAGGATTCTGGGAGGTCCAGCTGGCATCCCCATCCGGCCGGCTGAAGA  
 10 AGAAGAAGAGCGTGACCGTGTGGACGTGGCGACGCTTACTTCAGCGTCCCTCTGGACGAG  
 GACTTTAGAAAGTACACCGCCTTACCATCCATCTATCAACAAACGAGACCCCTGGCATCAG  
 ATATCACTACACGTCCCTCCCCAGGGCTGGAAGGGCTCTCCCGCCATTTCCAGAGCTCCA  
 TGACCAAGATCCTGGAGCCGTTCTGGAGAAGCAGAACCCCGATATCGTCATCTACCAAGTACATG  
 GACGACCTGTACGTGGCTCTGACCTGGAAATCGGGCAGCATCGCACGAAGATTGAGGAGCT  
 15 GAGGCAGCATCTGCTGAGATGGGGCTGACCACCTCCGGACAAGAACGATCAGAACGGAGCCGC  
 CATTCTGTGGATGGGCTACGAGCTCCATCCCGACAAGTGGACCGTGCAGCCTATCGTCCTC  
 CCCGAGAACGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTCAACTGGGC  
 TAGCCAGATCTATCCCAGGATCAAGGTGCGCCAGCTCTGCAAGCTGCTGCGCCGACCAAGG  
 CCCTGACCGAGGTGATTCCCTCACGGAGGAAGCCGAGCTCGAGCTGGCTGAGAACCGGGAG  
 20 ATCCTGAAGGAGCCCGTGCACGGCGTGTACTATGACCCCTCAAGGACCTGATCGCCGAAAT


Title: Method

Inventor(s): Ralph Patrick BRAUN et al.

DOCKET NO.: 036481-0151

CCAGAAGCAGGGCCAGGGCAGTGGACATACCAAGATTTACCAAGGAGCCTTCAAGAACCTCA  
 AGACCGGCAAGTACGCCGCATGAGGGCGCCACACCAACGATGTCAAGCAGCTGACCGAG  
 GCCGTCCAGAAGATCACGACCGAGTCCATCGTGATCTGGGGAAAGACACCCAAGTTCAAGCT  
 GCCTATCCAGAAGGAGACCTGGGAGACGTGGTGGACCGAATATTGGCAGGCCACCTGGATTC  
 5 CCGAGTGGGAGTCGTGAATACACCTCCTCTGGTGAAGCTGTGGTACAGCTCGAGAAGGAG  
 CCCATCGTGGCGCGGAGACATTCTACGTGGACGGCGCGCCAACCGCGAAACAAAGCTCGG  
 GAA  
 GCCGGGTACGTACCAACGGGGCCAGAAGGTGTCACCCCTGACCGACACCACCAACC  
 AGAAGACGGAGCTGCAGGCCATCTATCTCGCTCTCAGGACTCCGGCTGGAGGTGAACATC  
 10 GTGACGGACAGCCAGTACCGCCTGGCATTATTCAAGGCCAGCCGACCAGTCCGAGAGCGA  
 ACTGGTGAACCAGATTATCGAGCAGCTGATCAAGAAAGAGAAGGTCTACCTCGCCTGGGTCC  
 CGGCCATAAGGGATTGGCGCAACGAGCAGGTCGACAAGCTGGTGAGTGCAGGGATTAGA  
 AAGGTGCTGTAA

15 MGPISPIETV SVKLKPGMDG PKVKQWPLTE EKIKALVEIC TEMEKEGKIS  
 KIGPENPYNT PVFAIKKKDS TKWRKLVDFR ELNKRTQDFW EVQLGIPHPA  
 GLKKKKSVTV LDVGDAYFSV PLDEDFRKYT AFTIPSINNE TPGIRYQYNV  
 LPQGWKGSPA IFQSSMTKIL EPFRKQNPDI VIYQYMDLY VGSdleIGQH  
 RTKIEELRQH LLRWGLTPD KKHQKEPPFL WMGYELHPDK WTVQPIVLPE  
 20 KDSWTVNDIQ KLVGKLNWAS QIYPGIKVRQ LCKLLRGTKA LTEVIPLTEE  
 AELELAENRE ILKEPVHGKV YDPSKDLIAE IQKQGQGQWT YQIYQEPFKN  
 LKTGKYARMR GAHTNDVKQL TEAVQKITTE SIVIWGKTPK FKLPIQKETW  
 ETWWTEYWQA TWIPEWEFVN TPPLVKLWYQ LEKEPIVGAE TFYVDGAANR  
 ETKLGKAGYV TNRGRQKVVT LTDTTNQKTE LQAIYLALQD SGLEVNIIVTD  
 25 SQYALGIIQQA QPDQSESELV NQIIIEQLIKK EKVYLAWVPA HKGIGGNEQV  
 DKLVSAGIRK VL\*



### Title; Method

Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

Figure 23

**CD8, Interferon Gamma ELISPOT Results, from Day 14 C57Bl/6 Mice Vaccinated with Plasmid DNA Encoded with the HPV16 E7 Oncogene.**





Figure 24

**CD4 Peptide, IFNg ELISPOT  
E7 DNA Vaccine with and without TC-1 Cells(TC-1#7)**



**Title: Method**  
**Inventor(s): Ralph Patrick BRAUN et al.**  
**DOCKET NO.: 036481-0151**

Figure 25





Figure 26

**Tumor Measurements in C57BL/6 Mice Injected with HPV16 Tumor Cells and Vaccinated with an HPV16 E6 DNA Plasmid**



Title: Method  
 Inventor(s): Ralph Patrick BRAUN et al.  
 DOCKET NO.: 036481-0151

44/44

Figure 27





Figure 28



Title: Method  
Inventor(s): Ralph Patrick BRAUN et al.  
DOCKET NO.: 036481-0151

## Application Data Sheet

### Application Information

**Application Type::** Provisional  
**Subject Matter::** Utility  
**Suggested classification::**  
**Suggested Group Art Unit::**  
**CD-ROM or CD-R?::** None  
**Computer Readable Form (CRF)?::** No  
**Title::** METHOD  
**Attorney Docket Number::** 036481-0151  
**Request for Early Publication?::** No  
**Request for Non-Publication?::** No  
**Suggested Drawing Figure::** 1  
**Total Drawing Sheets::** 41  
**Small Entity?::** No  
**Petition included?::** No  
**Secrecy Order in Parent Appl.?::** No

### Applicant Information

**Applicant Authority Type::** Inventor  
**Primary Citizenship Country::** US  
**Status::** Full Capacity  
**Given Name::** Ralph Patrick  
**Family Name::** BRAUN  
**City of Residence::** Middleton  
**Country of Residence::** WI  
**Street of mailing address::**  
**City of mailing address::** Middleton

**State or Province of mailing address::** WI

**Postal or Zip Code of mailing address::** 53711

**Applicant Authority Type::** Inventor

**Primary Citizenship Country::** US

**Status::** Full Capacity

**Given Name::** Lichun

**Family Name::** DONG

**City of Residence::** Middleton

**State or Province of Residence::** WI

**Country of Residence::** US

**Street of mailing address::**

**City of mailing address::** Middleton

**State or Province of mailing address::** WI

**Postal or Zip Code of mailing address::** 53562

#### **Correspondence Information**

**Correspondence Customer Number::** 27476

**E-Mail address::** PTOMailWashington@Foley.com

#### **Representative Information**

<b>Representative Customer Number::</b>	22428	
---	-------	--

#### **Domestic Priority Information**

<b>Application::</b>	<b>Continuity Type::</b>	<b>Parent Application::</b>	<b>Parent Filing Date::</b>

**Foreign Priority Information**

<b>Country::</b>	<b>Application number::</b>	<b>Filing Date::</b>	<b>Priority Claimed::</b>

**Assignee Information**

**Assignee name::**

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/033391

International filing date: 12 October 2004 (12.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/567,771  
Filing date: 05 May 2004 (05.05.2004)

Date of receipt at the International Bureau: 11 November 2004 (11.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse